No retraction, correction or concern found when last checked on Oct 16, 2026.

Diabetic vascular diseases: molecular mechanisms and therapeutic strategies

Yiwen Li, Yanfei Liu, Shiwei Liu and 5 more

Signal Transduction and Targeted Therapy · 2023 · Review · CC BY

Abstract

Vascular complications of diabetes pose a severe threat to human health. Prevention and treatment protocols based on a single vascular complication are no longer suitable for the long-term management of patients with diabetes. Diabetic panvascular disease (DPD) is a clinical syndrome in which vessels of various sizes, including macrovessels and microvessels in the cardiac, cerebral, renal, ophthalmic, and peripheral systems of patients with diabetes, develop atherosclerosis as a common pathology. Pathological manifestations of DPDs usually manifest macrovascular atherosclerosis, as well as microvascular endothelial function impairment, basement membrane thickening, and microthrombosis. Cardiac, cerebral, and peripheral microangiopathy coexist with microangiopathy, while renal and retinal are predominantly microangiopathic. The following associations exist between DPDs: numerous similar molecular mechanisms, and risk-predictive relationships between diseases. Aggressive glycemic control combined with early comprehensive vascular intervention is the key to prevention and treatment. In addition to the widely recommended metformin, glucagon-like peptide-1 agonist, and sodium-glucose cotransporter-2 inhibitors, for the latest molecular mechanisms, aldose reductase inhibitors, peroxisome proliferator-activated receptor-γ agonizts, glucokinases agonizts, mitochondrial energy modulators, etc. are under active development. DPDs are proposed for patients to obtain more systematic clinical care requires a comprehensive diabetes care center focusing on panvascular diseases. This would leverage the advantages of a cross-disciplinary approach to achieve better integration of the pathogenesis and therapeutic evidence. Such a strategy would confer more clinical benefits to patients and promote the comprehensive development of DPD as a discipline.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 16, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Diabetes mellitus (DM) and its complications pose a serious threat to human health and have become a global public health issue., Over 90% of patients with diabetes have type 2 DM (T2DM)., Diabetic complications can be classified according to the involvement of cardiopathy and encephalopathy, nephropathy, retinopathy, and peripheral vasculopathy.– DM increases the risk of all these complications, and multiple vasculopathy is associated with a poorer prognosis. Recent intensive investigations into diabetic complications have significantly promoted the understanding of the pathogenesis of this disease. However, the increasing division of medical science into various subspecialties, has resulted in a tendency to focus on localized lesions instead of integrating overall evidence. Thus, a holistic investigation of diabetic complications involving multiple systems and different angiopathies is needed.

2The pathology of diabetic complications has a high degree of commonality at the vascular level; that is, complications manifest mostly as endothelial dysfunction and atherosclerosis (AS). DM being a risk factor for vascular disease, the several vascular comorbidities seriously affect the prognosis and treatment of patients, leading to the concept of “panvascular disease”.– Since the late 20th century, the concept of a “vessel tree” has been proposed and “polyvascular atherosclerotic disease” has been defined considering coronary and non-coronary AS, mainly peripheral arterial and cerebrovascular diseases (peripheral vascular disease and cerebrovascular disease respectively). This definition indicates that comprehensive management of the multivessel disease is clinically essential for improving outcomes and prognoses. However, this definition does not consider either microvascular disease (especially in vital organs) or multidisciplinary fusion. To improve this definition, we propose the concept of diabetic panvascular disease (DPD). This is a clinical syndrome in which AS is a common pathology between macrovessels and microvessels in the cardiac, cerebral, renal, ophthalmic, and peripheral systems in patients with diabetes. The main outcomes would be cardiovascular and cerebrovascular events, and the prognosis could be improved through aggressive intervention against metabolic abnormalities.

3Diabetic complications are usually classified in two dimensions: macro/microvascular disease, or complications classified by target organs. DPDs synthesize these concepts. This article systematically reviews general pathological manifestations of vascular lesions and differences in the etiology of macro/microvascular lesions; pathological manifestations and molecular mechanisms of different target organs in DPDs; common molecular mechanisms and therapeutic targets in DPDs; time course characteristics of pathological changes in organs and mutual predictive effects among DPDs to provide clues for early diagnosis. Our findings should promote the establishment of a multidisciplinary DPD management system.

Diabetes and panvasculopathy

4The vasculature comprises endothelial cells (EC), smooth muscle cells (SMC), pericytes, fibroblasts, and various other types of cells. AS, endothelial barrier damage, loss of pericytes, capillary thinning, and angiogenic disorders are common pathologies of systemic vascular disease. Blood vessels, together with nerves and lymphatic vessels, are wrapped in connective tissue membranes to form vascular nerve bundles. Differences in perivascular tissues, vascular nerve bundles, and intravascular structures result in altered vascular function. When imbalanced homeostasis is characterized by abnormal glucose and lipid metabolism, activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) directly or indirectly causes widespread vascular damage throughout the body, leading to the development of panvascular complications of DM (Fig. 1). SNS dominates vasoconstriction and RAAS regulates of blood volume, vascular tone, and blood pressure. The vascular system in target organs is tightly regulated by surrounding tissues that regulate microvascular units through physical and signal transduction. As DM progresses, patients are more likely to develop various vascular complications and experience many pathological changes, such as endothelial dysfunction, AS, and microcirculatory disorders that interact with each other, consequently leading to the development of DPD.

5Diabetic vasculopathy is classified as macroangiopathy and microangiopathy. Macroangiopathy includes AS of large and medium arteries (aorta, coronary, renal, basilar, and peripheral arteries), whereas microangiopathy includes endothelial damage to vessels between primary arterioles and venules, vascular basement membrane thickening, microthrombosis, platelet and red blood cell adhesion aggregation, and microcirculatory disorders. Due to differences in hemodynamics, vascular structure, and the affected cells, macro/microangiopathy present with different pathological manifestations. AS often occurs in sites of hemodynamic disturbances (preferably in elastic arteries). It manifests as macrophage foaming and EC lesions as well as mesangial SMC lesions. Microvessels are more hemodynamically stable, with a few cell layers, accompanying abundant plexus. On the other hand, differences in energy metabolic status, and organ-specific growth factors or cytokines in different target organs are also important components of the differences. Most target organs (heart, brain, peripheral vasculature) are affected by both diabetic macrovasculopathy and microvasculopathy; the retina and kidney are mainly affected by microvasculopathy (Fig. 1).

Diabetic heart disease (DHD)

6DHD includes all kinds of cardiovascular diseases secondary to DM, including coronary artery disease (CAD) and cardiomyopathy. Cardiomyopathy and CAD are often treated separately as microvascular and macrovascular diseases, DM can increase the risk of both. They are often combined in clinical settings and ultimately lead to adverse outcomes and risk of death in patients with cardiovascular disease.

7Myocardial microvascular functional changes precede structural changes in patients with diabetes. These changes finally lead to extensive macrovascular AS. DM complicated with coronary atherosclerotic heart disease manifests as the segmental distribution of numerous vascular branches throughout the entire process, with obvious AS. Diabetic cardiomyopathy (DCM) refers to specific myocardial structural and functional abnormalities that occur in patients without CAD and cardiac risk factors such as hypertension, with heart failure (HF) as the main manifestation of chronic cardiovascular complications of DM. The main pathological features are left ventricular hypertrophy, myocardial fibrosis, cell necrosis, and other myocardial structural changes., Myocardial involvement in vasoactive metabolite secretion or neuromodulation causes changes in the coronary artery wall pressure or endothelial shear stress. Pericoronary adipose tissue can secrete adipokines and other vasoactive mediators and/or oxidative products that can directly alter the phenotypes of perivascular adipocytes.

8Investigations of biomarkers of DHD and their applications have significantly progressed. Cardiovascular events as outcomes are more beneficial for the clinical application of biomarkers from the aspect of panvascular diseases. The severity of cardiovascular disease in patients with diabetes positively correlates with the ratio of oxidized low-density lipoprotein to low-density lipoprotein-cholesterol (Ox-LDL/LDL-C). This is considered a potential biomarker for the early identification and intervention of CAD in patients with diabetes. Osteopontin (OPN) is a multifunctional phosphorylated glycoprotein, that functions as an inflammatory cytokine and pro-atherosclerotic factor. High levels of OPN expression in the circulation and tissues are associated with cardiovascular complications in DM, and OPN is an independent predictor of cardiovascular disease in DM. Serum homocysteine levels are elevated in patients with T2DM and CAD and are closely related to the severity of coronary artery lesions. Plasma-free fatty acids also comprise an independent risk factor for CAD in patients with DM. Novel biomarkers are useful for providing insights into associations between DM and cardiovascular risk and developing treatment strategies for CAD associated with DM.

9Coronary AS exists in diabetic patients, and the signal transduction of AS is similar in DPDs. Chronic inflammation, abnormal lipid metabolism, and secondary autoimmunity are the main mechanisms. ApoB-specific CD4 T cells have been identified in humans and mice, and treg can be induced with ApoB peptides. Hsp60/65 is the target antigen of autoimmune T Cells. Hyperglycemic states can further promote autoimmune responses. In addition to glycemic control and statins, monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), heat shock proteins60/65 (HSP60/65), and ApoB are expected to improve AS by targeting.

10The mechanisms by which diabetes promotes cardiomyopathy have received attention, especially due to abnormal cardiac metabolism (Cardiac Metabolism), glycotoxicity and lipotoxicity, and abnormal mitochondrial function causing oxidative stress and inflammation. Unlike other target organs, the myocardium has high energy and oxygen requirements, and fatty acid oxidation (FAO) and aerobic oxidation of glucose are the main sources of energy for cardiac metabolism. Insulin resistance increases lipid synthesis in hepatocytes and lipolysis in adipocytes, leading to elevated circulating fatty acids and triglyceride levels. Lipid accumulation and fatty acids-induced lipotoxicity can affect myocardial FAO processes, promote endoplasmic reticulum (ER) stress, autophagy, and apoptosis, and cause ventricular remodeling., The most important metabolites of diabetic glycotoxin are advanced glycation end-products (AGEs) that are involved in the formation and evolution of DCM. These end-products bind cellular receptors of AGEs (RAGEs) that promote the production of reactive oxygen species (ROS), nuclear factor kappa-B (NF-κB), and pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, IL-18, tumor necrosis factor-alpha (TNF-α) that induce the intracellular production of abundant ROS, and initiate oxidative stress/inflammation cascade., AGEs/RAGE causing structural changes in the myocardium. Advanced glycation end-products also activate inflammatory signals through RAGEs on EC macrophages, and smooth muscle cells. This activation leads to increased ROS production and reduced nitric oxide synthesis, thus promoting the development of DCM., Hyperglycemia mediates a decrease in the expression of jund proto-oncogene subunit (JunD) and of free radical scavenger superoxide dismutase 1 and aldehyde dehydrogenase 2. It also mediates increased expression of inflammatory mediators such as NF-κB and Mcp-1, IL-6, and TNF-α that cause myocardial dysfunction and lead to the development of HF. Hyperglycemia promotes the increased expression of lncDACH1, which in turn promotes mitochondrial oxidative stress and apoptosis through increased ubiquitination-mediated degradation of NAD-dependent deacetylase sirtuin-3 (SIRT3), mitochondrial in mouse hearts, consequently aggravating DCM. Protein kinase C (PKC) is an effector in the G protein-coupled receptor system, and vascular SMC maintains vascular tone. PKC can be activated by excess ROS, AGEs, and diacylglycerol (DAG) to impair VSM function; this leads to vascular hyperresponsiveness and remodeling and accelerated development of DHD., Hyperglycemia triggers classical inflammatory pathways and oxidative stress., Hyperglycemia causes upregulates membrane cofactor protein-1 (MCP-1) and NLR family pyrin domain containing 3 inflammasome (NLPR3) expression, causing myocardial fibrosis and cardiac dysfunction, and exacerbated DCM development. Several molecular mechanisms synergistically act to impair the structural function of the heart and promote the development of DHD (Fig. 2).

11Various interventions have conferred clinical benefits on patients with DHD (Table 1). Treatment of DHD should be comprehensive, with aggressive control of risk factors such as blood glucose, blood pressure, and lipids. Basic pharmacological therapy for CAD in patients with diabetes includes antiplatelet, cholesterol-lowering, anti-myocardial ischemia strategies, and RAAS inhibitors. Aggressive blood sugar control is necessary for treating DHD to avoid direct hyperglycemic damage. When treating T2DM complicated with cardiovascular disease, metformin should be combined with glucose-lowering drugs that have a proven cardiovascular benefit. When treating T2DM complicated with atherosclerotic cardiovascular disease, the preferred combination of metformin with either glucagon-like peptide-1 receptor agonist (GLP-1RA) or sodium/glucose cotransporter-2 inhibitors (SGLT-2i) can reduce cardiovascular events (Table 1). When treating T2DM complicated with HF, metformin should be combined with SGLT-2i, as this leads to a 39% reduction in the risk of HF hospitalization and a 46% reduction in the composite endpoint of HF hospitalization with all-cause death. Although GLP-1RA and dipeptidyl peptidase-4 inhibitors (DPP-4i) also confer some cardiovascular benefits, they do not offer a significant advantage for reducing the hospitalization of HF in patients with diabetes (Table 1).,,

Diabetic encephalopathy (DE)

12DM is significantly associated with an increased risk of several intracranial diseases, including cerebral macro- and microangiopathy.– Broadly speaking, the intracranial complication of DM includes stroke, which can also manifest as depression, mild cognitive impairment (MCI), and dementia.,– Such vascular lesions can involve large carotid and vertebral arteries, small intracerebral perforating arteries, micro-arteries, capillaries, micro-venules, and small veins. They are also involved in disrupting the integrity of the blood-brain barrier (BBB) and neurodegeneration., The cerebral microvasculature facilitates intracranial nutrient delivery and waste removal, supports neuronal activity, maintains the interstitial environment, and reduces and stabilizes blood flow. Diabetic macroangiopathy and microangiopathy mutually promote each other, and the occlusion of macrovessels can cause chronic perfusion insufficiency in the brain and microvascular disorders. Microvascular function can affect collateral circulation in macrovessels, and increase the risk of stroke as well as a poor prognosis.– Neurons injury, Alzheimer’s like pathologies, and abnormal activity of neurotransmitter receptors are also closely associated with cerebrovascular lesions, and jointly cause brain function impairment in patients.

13Elevated blood glucose is a risk factor for pathological changes in the brain and brain function impairment., Not only DM but also pre-DM can promote the development of dementia. However, the imaging changes do not correspond to the degree of cognitive impairment, and its mechanism deserves further exploration. Diabetic cerebral microangiopathy has multiple complex changes in images (cerebral atrophy, subcortical microinfarcts, cerebral white matter hyperintensity, lacunar infarction, perivascular space, and cerebral microhemorrhage), with diffuse adverse effects., Meanwhile, advances are being made in the measurement of cerebral microangiopathy, along with more precise MRI interpretations and artificial intelligence that have revealed more DM-induced cerebrovascular pathologies.

14Intracranial pathological changes of microangiopathy include endothelial dysfunction, platelet aggregation impairment, and increased inflammation.– The expression of vascular endothelial growth factor (VEGF) and endothelin nitric oxide synthase (eNOS) are decreased in DE, which impairs cerebral artery endothelial function and results in decreased vascular autoregulatory response. Disorders of platelet aggregation and inflammation reduce cerebral blood flow and increase the risk of DE. Central nervous system is highly dependent on glucose for energy supply.– Disturbance of carbohydrate metabolism can cause an intracranial energy metabolism imbalance and promote lesion development., Aldose reductase activity is significantly and systemically increased with hyperactivation of the sorbitol pathway in diabetes. This leads to insulin resistance, resulting in widespread oxidative stress and increased inflammatory cytokines. The insulin receptor signaling system plays an important role in maintaining normal brain and cognitive functions by regulating GLP-1 receptors,, insulin receptor substrate (IRS) receptors., In other tissues, insulin activates the glucose transporter (GLUT) family of glucose transport proteins, but in the skull GLUT is directly regulated by glucose or cAMP. Activation of IRS or GLUT promotes glucose utilization in the Phosphatidylinositide 3-kinases (PI3K), protein kinase B (Akt), and β-arrestin/ extracellular regulated protein kinases (ERK) pathways. Insulin resistance causes chronic inflammation and increased oxidative stress, imbalanced energy metabolism.– This leads to neuroinflammation and the apoptosis of pericytes and microglial cells,,,– thus disrupting vascular endothelial tight junctions and causing damage to the BBB. The accumulation of AGEs also affects various cellular constituents of the BBB, resulting in increased BBB permeability and cognitive impairment.– Vascular endothelial dysfunction further promotes the production of inflammatory mediators that disrupt the BBB,,,, which exposes the brain parenchyma to potentially neurotoxic proteins. Classical inflammatory mediators such as IL-1β, IL-6, IL-10, TNF-α, vascular cell adhesion protein-1 (VCAM-1), and matrix metalloproteinases (MMP)-2 and -9 suggest vascular neuroinflammation. Intracranial-specific inflammatory signals, estrogen receptors promote increased expression of membrane Rα and ERβ in the hippocampus and promote hippocampal apoptosis; P38 activates mitogen-activated protein kinase (MAPK) pathway to promote neuronal cell death, and microglia activation., Hyperglycemia stimulates inflammatory signals and adaptive signals, accelerating ER stress and mitochondrial dysfunction. In addition, glutamate is a key excitatory neurotransmitter in the central nervous system. Glutamate receptors, including N-methyl-d-aspartic acid receptors (NMDA), may regulate neurogenesis and synaptic plasticity., Upregulation of NMDA receptors had beneficial effects on learning and memory in diabetic rats (Fig. 3).

15The main therapeutic approaches target brain microvascular endothelium and the BBB, microvascular function, neuroinflammation, and antiplatelet agents., Maintaining normal blood glucose levels is essential, but no evidence supports intensive glucose-lowering regimens for patients with diabetes and cognitive impairment or dementia.– Moreover, the risk of hypoglycemic events is associated with cognitive decline and increased risk of dementia.,, Although lowering glucose is generally ineffective for preventing stroke and cognitive impairment, some drugs do provide these benefits in addition to controlling glucose levels. Metformin, pioglitazone, and GLP-1 agonizts that can cross the BBB are of interest in the treatment of DE. Metformin might improve cognitive impairment associated with stroke or Alzheimer’s disease,, and prevent dementia in persons aged <75 years more effectively than sulfonylurea hypoglycemic agents. Pioglitazone might reduce the risk of dementia by 47% in populations with diabetes. Pioglitazone and glitazones can activate peroxisome proliferator-activated receptor-γ (PPAR-γ), which can improve cell adhesion factors and inflammatory factors in brain cells. This receptor can also act on other tissues and regulate glucose metabolism and overall energy homeostasis. Abundant GLP-1α is expressed in the brain, and GLP-1 receptor agonizts have a good safety profile, neuroprotective effects, and can improve cognitive impairment. The new glucose-lowering agent SGLT-2i has cardio-renal protective effects, but it might increase the risk of stroke, which makes its use controversial.– Furthermore, the mechanism of SGLT-2i actions is unknown. Meanwhile, new benefits have been confirmed for some traditional hypoglycemic agents, such as glibenclamide, which can reduce hemispheric edema after stroke when intravenously injected., Among non-hypoglycemic drugs, phosphodiesterase type III inhibitor Cilostazole improves oxidative stress and regulates cerebrovascular damage. NMDA receptor agonizts, neurotrophic factors, and mitochondrial function modifiers are also under development.

16Imaging modalities such as MRI are significantly more important than serum markers for identifying encephalopathy compared with other diabetic vascular lesions. However, current imaging protocols for diagnosing DE are not sufficiently specific. The correlation between imaging and corresponding molecular mechanisms is not yet clear. To overcome this limitation, large clinical trials targeted other vascular lesions and glycaemic control need to be conducted, to identify the population with diabetes that is at high risk of developing cerebrovascular lesions.

Diabetic kidney disease (DKD)

17Between 5 and 40% of patients with diabetes eventually develop diabetic kidney disease (DKD), and the number of those with chronic DKD is increasing by 2.62 million annually, with chronic DKD being the leading cause of end-stage renal disease. DKD is a microvascular complication characterized by glomerular hypertrophy, basement membrane thickening, and damage. The complex renal vascular system, including the renal arteries and their branches, as well as glomerular and peritubular capillary networks, form the basis for maintaining normal renal function. The mechanism through which DM causes kidney damage is complex and might involve hemodynamic, metabolic, and inflammatory pathways and targets, (Fig. 4). A hyperglycemic environment induces hypertension, which increases the disturbed renal perfusion pressure and indirectly causes microvascular damage in renal arteries, glomerular and tubulointerstitial capillaries.– AS causes thickening of renal artery walls and lumen narrowing., Upregulated SGLT expression promotes glucose uptake, which affects the tubular-glomerular feedback mechanism, leading to glomerular hypertension., Plasma levels of kallikrein, thrombin, and coagulation factors are elevated in hyperglycemic states. A chronically activated coagulation system is closely associated with a vascular injury in patients with DKD.

18The most prevalent diagnostic markers for DKD are the estimated glomerular filtration rate (eGFR) and proteinuria calculated based on serum creatinine or cystatin C. However, tissue damage is often irreversible by the time a diagnosis is confirmed, and new biomarkers are needed to diagnose DKD earlier and to stratify risk factors. Current new biomarkers mainly target diagnoses of inflammation, endothelial damage, fibrosis, endothelial dysfunction, and kidney damage, including TNF-α receptor, intercellular adhesion molecule-1, endostatin, copeptin, kidney injury molecule-1,, monocyte chemoattractant protein-1, and neutrophil gelatinase-associated lipocalins. Extracellular vesicles have recently attracted interest, because they are essentially exosomes and particles that transport miRNA, mRNA,, and proteins, and might serve as early biomarkers of DKD. In addition to individual biomarkers, other approaches such as proteomics, genomics, and metabolomics all play roles in screening, especially in studies of chronic kidney disease (CKD) which can predict the development of proteinuria. Despite many studies of novel biomarkers, only eGFR and proteinuria are routinely applied to clinically diagnose DKD, and the specificity and accuracy of these awaits clarification in future controlled clinical trials with large samples.

19In addition, imbalanced pro- and anti-angiogenic factors can disrupt the vascular network in DKD. Hyperglycemia increases glomerular capillary pressure through a RAAS-mediated increase in angiotensin II., Hyperglycemia-mediated changes in glomerular capillary autoregulation can cause endothelial dysfunction and inflammation by increasing transforming growth factorβ-1 (TGFβ-1) mediated ROS that dilates glomerular afferent and efferent arterioles. Lipid metabolism is often abnormal in patients with diabetes, and this can also contribute to glomerular and tubulointerstitial vascular injury through mediators such as cytokines, ROS, and hemodynamic changes., Hypoxia in renal tissues due to reduced density of tubulointerstitial capillaries is also a major cause of renal disease progression., Although scant vascular endothelial growth factor A (VEGFA) is expressed in renal tubular capillaries, the absence of specific VEGFA expression leads to a significant decrease in peritubular capillary density in mice. However, overexpression causes dilation of peritubular capillaries.

20Inflammatory mediators (chemokines, cytokines, and adhesion molecules), are often released due to hyperglycemia and hemodynamic abnormalities, which lead to nephron damage through ultrafiltration, mechanical stress, oxidative stress, glycocalyx dysfunction, and endothelial activation., These mediators cause renal microvascular dilation or altered permeability through thylakoid proliferation, podocyte or tubular injury, and inflammatory cell infiltration. In addition, oxidative stress is closely associated with inflammation and causes endothelial dysfunction by activating NF-κB, and adapter protein complex-1, to induce pro-inflammatory factors and, in turn, mediate the inflammatory response, thus inducing renal fibrosis. Therefore, the main causes of vasculopathy in DKD are inflammation, hemodynamic, and metabolic disorders. Lesions are mostly concentrated on the glomerular and tubulointerstitial microvasculature and also in other vessels such as renal arteries, and glomerular afferent and efferent arterioles. The pathogenesis and therapeutic strategies need further exploration.

21The current strategies for treating DKD mainly comprise controlling blood sugar and blood pressure and blocking the RAAS (Table 2). After controlling various risk factors such as hyperglycemia, hyperlipidemia, hypertension, and uric acid,, the risk of DKD is reduced, but the vascular disease continues to progress. Blood pressure control and fenofibrate can increase the risk of renal adverse events such as decreased eGFR, suggesting a need to explore more effective treatment modalities., Novel hypoglycemic agents might protect the kidney through combined actions against hyperglycemia, hypertension, lipotoxicity, abnormal tubuloglomerular feedback, hypoxia, endothelial dysfunction, and renal fibrosis. The SGLT-2i dapagliflozin exerts renoprotective effects, possibly by affecting the hemodynamics of patients mainly through post-glomerular vasodilation to normalize the eGFR. In addition to stimulating insulin secretion from pancreatic β-cells to control blood glucose, incretin might also bind to GLP-1 receptors to inhibit endothelial damage and thus exert positive effects. The large FIDELIO-DKD clinical trial found that finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist combined with a RAAS inhibitor, reduced the risk of cardiac and renal outcomes while reducing the incidence of hyperkalemia. MiRNAs play an important role in maintaining optimal vascular homeostasis and regulating microvasculature disorders. The miR-132 inhibitor CDR132L improves HF and affects cardiac fibrosis biomarkers and might also have a therapeutic effect on renal fibrosis. Anticoagulants might hamper the progression of DKD, but the clinical application requires further validation and tests, as some anticoagulants such as vorapaxar might increase bleeding risk (Table 2).

22Some pathways associated with kidney injury have emerged as novel targets for treating DKD. For example, baricitinib is an oral small-molecule inhibitor that selectively inhibits the Janus kinase (JAK) protein tyrosine kinase family members JAK1 and JAK2, which inhibits the JAK-mediated inflammatory pathways and reduces proteinuria. Small-molecule inhibitors associated with kidney damage, such as the vascular adhesion protein-1 inhibitor ASP8232, reduce proteinuria through local effects on glomeruli and podocytes, offering potential multi-target interventions. Another promising therapeutic target is gut flora, as the renal disease causes the dysbiosis of various gut microbes. Inhibiting phenyl sulfate (a metabolite derived from gut microbiota) reduces proteinuria in mice with DKD. Supplementing patients with diabetes who are on hemodialysis with probiotics improves glucose and lipid metabolism, as well as biomarkers of inflammation and oxidative stress. Orally administered Faecalibacterium exerts both anti-inflammatory and renoprotective effects on patients with CKD through butyrate-mediated G protein-coupled receptor-43 signaling. Moreover, traditional Chinese medicine has also achieved considerable progress in DKD treatment, as a combination of Huangkui capsules and irbesartan was found to be more effective than either of the medications alone in reducing albumin-to-creatinine ratio in patients with DKD, suggesting the potential role of Chinese medicine in future DKD therapy.

23Renal microvasculature is an important target of DPD. Intensive management of DM, including controlling blood sugar and blood pressure and blocking the RAAS, will reduce the incidence of CKD and delay its progression. Current and future health resource requirements for DKD treatment are difficult to estimate. Thus innovative therapeutic strategies are needed to prevent, block, treat, and reverse DKD.

Diabetic retinopathy (DR)

24DR is one of the most common microvascular complications of DM., Pathological changes of DR start with the loss of retinal neuronal. The series of events include early loss of neurovascular coupling, retinal neurodegeneration, and subsequent gliosis, finally leading to retinal vasculopathy. Microvasculopathy in the DR retina are manifested as loss of retinal capillary epithelial cells, decreased capillary elasticity, and increased vascular permeability, exudation, local inflammation, and growth factors promoting neovascularization., DR is clinically classified as non-proliferative (NPDR) or proliferative (PDR) in the absence or presence of retinal neovascularization, respectively. The NPDR type progresses to PDR and eventually develops into macular edema, with the latter being an important cause of vision loss or blindness in patients with diabetes., Such patients must undergo regular fundus examinations to detect vision-threatening stages of DR, such as PDR and diabetic macular edema, as early as possible to treat them before vision loss becomes irreversible.

25Delayed diagnosis and treatment are the most common causes of visual impairment in patients with diabetes. Therefore, the early detection and prevention of lesions in DR is the key to stop DR progression. Biomarker-related biomic and artificial intelligence (AI) investigations will play increasingly important roles in the risk assessment, early diagnosis, and treatment of the disease. Homocysteine levels are significantly high in the serum of patients with diabetes and should become a screening and diagnostic indicator of DR, as its prevention and treatment can be targeted by increasing homocysteine clearance. The main factor controlling neovascularization is VEGF, levels of which increase in vitreous and tear fluids from patients with DR and correlate positively with DR severity. Retinol-binding protein 3 (RBP3) is a retinol transporter protein secreted by photoreceptors, and high levels of RBP3 in the vitreous body of patients with diabetes slow DR progression. Elevated RBP3 expression can alleviate hyperglycemia-induced DR by inhibiting glucose uptake by glucose transporter protein-1 and reducing the expression of inflammatory cytokines and VEGF. Therefore, RBP3 could serve as a biomarker and therapeutic strategy in preventing the progression of DR. MiRNAs are involved in retinal neovascularization and the inflammatory response in DR. The relative expression of serum miRNAs was measured in 80 patients with T2DM comprising an NPDR group with normal, mild, moderate, or severe symptoms and a PDR group. The results showed that the relative expression of serum miR-146a and miR-21 increased, whereas that of miR-34a decreased with worsening DR severity. miR-125a-5p significantly attenuated vascular leakage in DR. These findings suggested that miR-146a, miR-21, miR-34a, and miR-125a-5p could serve as promising biomarkers for DR. AI has recently become a research hotspot in auxiliary medical diagnosis. Ophthalmic AI integrates imaging databases with deep learning (DL) technology to automatically measure and analyze the characteristic biological structures of the eyes of patients with DR to assist with diagnosis. We found different features of Hematoxylin-eosin-stained retinal sections from diabetic mouse models based on changes in nerve fiber layers and ganglion cells during the early stage of the disease. We then identified these features using image recognition and DL, and consequently identified changes in ganglion cells and the nerve fiber layer that could be applied to the early quantitative diagnosis of DR. Another AI-based study by our team quantified the pathological changes of retinal neurons and synapses in mice with diabetes induced by monosodium glutamate (MSG). We found that MSG-induced DR was closely associated with neurotransmitter abnormalities and had important features of retinal neurodegeneration, providing an effective animal model and technique for quantifying retinal neuron pathology.

26A thorough knowledge of the mechanism of DR is essential for its prevention and treatment. Hyperglycemia can lead to inflammation, oxidative stress, and increased glycosylation product and VEGF contents during the late stages. These can increase retinal permeability and alter retinal hemodynamics, leading to retinal leakage and the development of DR. Serine racemase (SR) promotes the formation of d-serine, which activates NMDA receptors and has multiple effects on neuron. Overexpression of SR in diabetic retinopathy leads to retinal neurodegeneration. Hyperglycemia subsequently leads to vascular EC damage, and in turn, leukocyte aggregation/adhesion to vessel walls. Leukocyte adhesion and aggregation activate a massive amount of neutrophils that adhere to EC and form a reticular network and aggravate tissue hypoxia, causing vascular remodeling and neovascularization. The main protein that mediates intercellular adhesion is intercellular cell adhesion molecule-1 (ICAM-1). Under inflammation, ICAM-1 is abundantly expressed in retinal EC, where it binds to receptors. This induces leukocytes to penetrate the endothelium and become adherent, indicating that ICAM-1 is an important mediator of the inflammatory response in DR., The inflammatory response of the retina in DR involves the production and release of various inflammatory factors. In particular, the release of massive amounts of IL-1β can lead to the apoptosis of retinal pigment epithelial cells, which damages the integrity of photoreceptors. IL-1β activates NF-κB and oxidative stress, leading to the apoptosis of capillary EC and increasing EC permeability. IL-1β also promotes IL-6 secretion and induces capillary angiogenesis by activating the NF-κB pathway and p38/MAPK. The pro-inflammatory factor TNF-α can cause EC damage and increase EC permeability, resulting in vascular leakage. Inflammatory factors induce each other via cascade amplification, mediating the inflammatory response and exacerbating DR. Oxidative stress leads to nerve, vascular, and retinal tissue damage and, in turn, the development of DR., Chronic hyperglycemia causes oxidative stress mainly through PKC, polyol, hexosamine, and AGEs formation pathways. Hyperglycemia can regulate vascular cell permeability, the extracellular matrix, cell growth, neovascularization, cytokine response, and leukocyte adhesion through the diacylglycerol-PKC pathway, leading to structural and functional changes of the retinal vasculature., Activation of the polyol pathway produces oxidative stress, which increases the consumption of reduced coenzyme II (NADPH) oxidase through the production of sorbitol by aldose reductase (AR), thus affecting the production of the antioxidant reduced glutathione and causing an oxidative-antioxidative imbalance.– The production and accumulation of sorbitol under hyperglycemic conditions increases retinal osmotic pressure, cell edema, metabolic disorders, and microvascular damage,, consequently aggravating DR. Advanced glycation end-products promote NF-kB activation by interacting with the cellular RAGEs on the cell surface. This leads to retinal pericyte apoptosis and elevated expression of VEGF, inflammatory cytokines, and adhesion molecules. Inhibition of ACEs can improve hyperglycemia-induced blood-retinal barrier leakage and reduce retinal EC proliferation, migration, and neovascularization, thus alleviating DR. The main hallmark of PDR is neovascularization. The most important inflammatory factor that stimulates neovascularization and causes vascular leakage is VEGF. Hypoxia-inducible factor-1α is activated under hyperglycemic and hypoxic conditions, which leads to increased secretion of VEGF, and overexpressed VEGF, in turn promotes neovascularization through activation of the PI3K/Akt,– PKC,, and NF-κB, signal pathways. The expression of ICAM and nitric oxide synthase induced by VEGF promotes leukocyte adhesion and causes changes in vascular permeability and pathological neovascularization.– The pathogenesis of DR is complex, with numerous factors that synergistically interact with each other during the development and progression of DR (Fig. 5).

27DR can be treated mainly by laser photocoagulation and vitreous injections of antibodies. Retinal laser photocoagulation can prevent further vision deterioration, but cannot restore damaged vision. Intravitreally injected ranibizumab and bevacizumab reduce the recurrence of active neovascularization and risk of retinal detachment. However, frequent intraocular administrations due to a short half-life increase the risk of retinitis, retinal obstruction, and patient pain and might facilitate the development of drug resistance., Intraocular glucocorticoid injection is often used to treat persistent and refractory diabetic macular edema, which improves vision but increases the incidence of cataracts and glaucoma. Drugs such as ranibizumab, aflibercept, and fenofibrate have been included in clinical trials to evaluate their effectiveness and safety (Table 3), thus providing new ideas for treating DR.

Diabetic peripheral vasculopathy (DPVD)

28DPVD is often overlooked, yet it is one of the most important and common vascular complications in patients with T2DM. In such patients, DPVD increases the risk of not only coronary atherosclerotic events, but also major adverse limb events such as amputation. DPVD can manifest as diabetic foot syndrome and peripheral arterial disease (PAD), which seriously affect the quality of life of patients with diabetes. Peripheral arterial disease is traditionally considered to be dominated by large artery AS. In fact, PAD is often accompanied by local and systemic microangiopathy., Multivessel endothelial dysfunction can manifest as microangiopathy (either exclusively or with other diseases), such as capillary basement membrane thickening, endothelial hyperplasia, oxygen tension reduction, and hypoxia, affecting peripheral nerve function. Pre-DM can affect blood vessels and accompanying nerves., The chronic course of DM might have further adverse effects under poor glycemic control., An increase in postprandial glucose plays an important role in the development of peripheral vascular disease in DM.

29The pathogenesis of DPVD overlaps with that of other AS and microvascular endothelial injuries. IL-6, high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and high-molecular-weight lipocalin biomarkers serve as indicators of the risk of cardiovascular disease and peripheral vascular disease.– Specific markers for DPVD are unknown, but many biomarkers of vascular injury are available., For example, circulating levels of ICAM and sE-selectin indicate EC activation and vascular inflammation, and thus have potential as diagnostic markers of DPVD.,

30The molecular mechanisms of AS in DPVD can be found in the section on coronary AS. Microvasculopathy in DPVD is highly concomitant with neuropathy, as microvessels form a neurovascular network with accompanying nerves. Neurons and Schwann cells are highly susceptible to hyperglycemia., Energy and inflammation, oxidative stress, insulin resistance, AGEs, nerve growth factors, activation of the polyol pathway, and activation of the hexosamine and PKC pathways are core pathological factors and processes similar to those of other DM vascular complications., Glucose and fatty acid metabolism, neural metabolism, and exosome regulation have recently attracted attention., Much more is known about peripheral neuropathy than about DPVD. Glucose overload and high fatty acid metabolism lead to decreased ATP production, excessive ROS formation, and impaired mitochondrial function, which further increases oxidative stress, leading to the formation of AGEs from the glycosylation of various proteins. The vicious cycle of these events further promotes ROS formation and ER stress, resulting in DNA damage and apoptosis of various cells. Abnormal neurometabolism in DM manifests as changes in sphingolipid metabolism, wherein sphingolipids are biologically active and important structural components of plasma cell membranes and are important signaling molecules. Abnormal sphingolipid metabolism causes neurotoxicity in patients with hyperglycemia. All of these pathways eventually manifest as increased pro-inflammatory factors that further induce AGEs production, leading to oxidative stress and endothelial dysfunction. These interactive processes simultaneously place EC and neurons in a state of oxidative stress and inflammation.

31The endpoint of DPVD is amputation, the occurrence of which is closely associated with infection and trauma. Therefore, care and lifestyle changes play an important role in its treatment, which greatly differs from the preventive measures for other vascular pathologies. Normal or near-normal glycemic control is a primary therapeutic goal. Intensified hypoglycemic therapy reduces the incidence of peripheral neuropathy in patients with T1DM but has a little additional benefit for those with T2DM., Systemic antioxidant and anti-inflammatory therapy might also provide some benefits. New glucose-lowering drugs can reduce blood glucose without increasing the risk of amputation. In a subgroup of patients with T2DM combined with PAD, empagliflozin reduced rates of mortality, hospitalization for HF, and the progression of kidney disease. Patients treated with the new glucose-lowering drugs SGLT-2i, GLP-1RA, and DPP-4i have low risks of amputation with a good safety profile. Some glucose-lowering agents have conferred advantages for patients with DPVD and other multivessel diseases. The results of the LEADER trial suggested that liraglutide could be used in diabetic multivessel diseases. These treatment options could improve the overall quality of life of patients.

Temporal progression of DPDs

32The time of onset of panvascular complications in patients with diabetes is closely associated with patient age, race, genetic background, DM staging, treatment regimen,, and level of glycemic control., The natural course of DPDs is not completely clear, but diabetic microangiopathy generally precedes diabetic macroangiopathy. Clinical trials of patients with insulin-dependent DM have found that DR develops within the first 2 years of DM in conventionally treated patients, and that by the fifth year, 25–40% of these patients develop retinal, renal, and peripheral microangiopathy. A Chinese cohort study has shown that >20% of patients develop moderate retinopathy and >40% develop mild proteinuria within 7 years after the onset of DM. According to the ADVANCED study, the incidence of macroangiopathy at the fifth year of DM does not exceed 10%. Complications with panvascular disease appear earlier and more frequently in patients with T2DM, than in those with T1DM., After adjusting for age and the duration of DM, the risk of peripheral neuropathy is found to be significantly higher in patients with T2DM than in those with T1DM. The median elapsed time to the onset of microproteinuria is also significantly shorter in adolescents with T2DM than in those with T1DM (1.3 vs. 6.8 years).

33The natural course of DPDs in rodents from the same genetic background would provide insights into the pathological changes in various tissues at the same time. Streptozotocin induced in C57BL/6 mice develop microangiopathy in various organs at 4‒20 (mostly 8‒10) weeks after the onset of DM;– db/db mice simulating type 2 diabetes develop microangiopathy in various organs at 16‒40 (mostly 20) weeks of age., The temporal progression of diabetic microvascular complications in mice are Concurrent regardless of the modeling modality (Fig. 6). DKD is the earliest to appear, with peripheral motor nerve conduction velocity decelerating at 4 weeks of DM (C57BL/6 mice). Microvascular function in diabetic mice partially changes around 8–10 weeks after DM onset (C57BL/6 mice),– or 20 weeks of age (db/db mice),,,, manifested as pathological staining of various organs changes. After 8 weeks of hyperglycemic state, further pathological changes of diabetic C57B/6 mice in microvascular structure can occur, including expansion of the mesangial matrix of renal microvasculature and rupture of the renal tubular epithelium The retinal ultrastructure changes, infoldings in retinal pigment epithelium layers are decreased, and balance or proprioception are impaired due to neurovascular disease. At 12‒20 weeks of DM, late panvascular disease can occur, with advanced vasculopathy of the heart, retina, or brain.– occurring slightly before that of the kidneys. Diabetic macroangiopathy does not develop spontaneously in rats after DM modeling; rather, it is generally induced through specific diet control or vascular occlusion of the DM model rats. Thus, after simply constructing animal models of diabetes, studies on microangiopathy and macroangiopathy in the same models are scant. Rodents have different lipoprotein metabolism from humans and are highly resistant to AS. C57BL/6 mice are relatively too resistant to intraperitoneal injections of STZ to construct a model of DKD, and various diabetic complications require different animals for optimal modeling. Therefore, the optimal animal model for DPD studies awaits further investigation and clinical evidence.

34Relationships among DPDs (Fig. 7) outcomes in vital organs (heart, kidney, and brain) are mutually predictive. DR is associated with coronary atherosclerotic heart disease, macrovascular events (including stroke), and all-cause mortality. Screening retinal microvessels have a potential role in the risk identification of cerebrovascular and neurodegenerative diseases. In T2DM, retinal parameters and a genome-wide polygenic risk score for coronary heart disease have independent and incremental prognostic value compared with conventional cardiovascular risk assessment. Risk of macrovascular complications in patients with diabetes and retinal artery occlusion for at least 5 years after an obstruction event is increased compared with those who do not have such occlusion. Therefore, retinopathy can predict cardiovascular risk in patients with T2DM. DR is closely associated with stroke– and cerebral microangiopathy. During embryonic development, the diencephalon is homologous to the retina and optic nerve, especially the capillary-linked microglia and neuronal synapses, which are abundant in the retina and brain and sensitive to blood glucose. The microvasculature of the retina and the axonal function of retinal ganglion cells can be detected using fundus photography and optical coherence tomography to assist with the diagnosis of cerebrovascular neuropathy. Retinal microvascular imaging findings closely correlate with cerebral infarction and white matter lesions, parapapillary retinal nerve fiber layer thickness, macular thickness, and volume being indicators of stroke risk. Changes in the retinal vasculature can predict various stroke subtypes, suggesting that retinal vascular changes reflect specific cerebral microangiopathy and might even distinguish stroke from other causes of focal neurological deficits. In contrast, qualitative retinal vascular signs and quantitative retinal vascular measurements of narrowing small retinal arteries and widening small retinal veins, might indicate a cognitive decline. Compared to that with stroke, the association of DR with dementia and cognitive decline is more limited, suggesting a need for further prospective studies. In addition, because risk factors for stroke differ between patients with and without diabetes, stroke risk prediction models should include data on DR and DKD, which is a topic for future studies. DKD increases the risk of stroke, cerebral infarction, and cerebral hemorrhage. However, some subclinical cardiovascular complications of DM are not associated with stroke. Retrospective studies have shown that DR is associated with the development of DKD and the decline of renal function.– Subsequent retrospective studies have found a positive association between DR and the risk of DKD progression., Retrospective findings of narrowing small retinal arteries and widening small veins both suggested the development of DKD, and this was later confirmed by a cross-sectional study and several prospective studies.– Diabetic macroangiopathy and neuropathy are also important risk factors for DKD. Prospective studies have shown that carotid plaques and aortic stiffness are associated with DKD progression., A retrospective cohort study found that coronary artery calcification played a similar predictive role. Two retrospective cohort studies found that peripheral neuropathy and cardiac autonomic neuropathy are strong predictors of DKD., As discussed, vasculopathy due to various diseases, especially DR, is generally predictive of DKD progression, providing evidence supporting the panvascular nature of DM.

Cellular energy metabolism

35Cellular energy metabolism requires energy supply from glucose, fatty acids, amino acids, etc., In the diabetic state, abnormalities in cellular energy metabolism affect macrovascular and microvascular lesions,– including abnormalities in substrate delivery to vascular EC or target organ cells (e.g., cardiac myocytes, thylakoid cells in glomeruli, and neurons and Schwann cells in peripheral nerves), conversion of the ratio of cell-specific fuel sources between glucose intermediates, fatty acids, and amino acids, changes in respiratory chain protein function, and uncoupling of respiratory chains.– The hyperosmolar state and abnormal energy metabolism of diabetes increase the PKC pathway, endothelial xanthine oxidase, and the eNOS uncoupling pathway, promoting increased ROS levels., The mechanisms of energy metabolism imbalance vary slightly between target organs with different mitochondrial content and different major energy supply substances.

Glucose metabolism

36Glucose metabolism is the main factor affecting cellular energy metabolism. The “unification hypothesis” suggests that several seemingly independent biochemical pathways that are overactivated in diabetes are actually caused by excessive intracellular glucose flux (Fig. 8). EC are extensively damaged in DPDs, and EC produce ATP mainly by glycolysis. In hyperglycemic states, changes in the metabolic pathways of sugar (increased flux of the hexosamine pathway, increased flux of the polyol pathway, decreased flux of pentose phosphate and glycolytic pathways) lead to decreased production of NADPH and increased ROS, exacerbating oxidative stress. In the pentose phosphate pathway, glucokinase/hexokinase is involved, and this enzyme also regulates glucose transport into cells, as well as glycogen metabolism and gluconeogenesis. Activation of glucokinases (Dorzagliatin, PB-201, AZD-1656, etc.) has a regulatory effect on glucose homeostasis,– but no additional vascular protective value has been reported yet.,

37Hyperglycemia reduces glucose-6-phosphate dehydrogenase (G6PDH)-mediated entry of glucose into the pentose phosphate pathway, but rather into the polyol pathway through conversion to sorbitol by the rate-limiting enzyme AR, and these processes are accompanied by a decrease in the rate of NADPH (an important intracellular reducing agent) production. Meanwhile, high glucose induces activation of NADPH oxidase (NOX) to produce ROS, increases oxidative stress levels, and promotes NLRP3/IL-1β and IL-18 to increase inflammation levels. Diabetes promotes the accumulation of fructose-6-phosphate (F6P), which can lead to an increase in the hexosamine (HBP) pathway and overproduction of UDPn-acetylglucosamine. UDPn-acetylglucosamine is involved in intracellular protein regulation, especially for post-translational modifications of proteins such as O-GlcNAcylation. The HBP pathway accounts for a small percentage of glucose metabolism and does not affect tissue energy supply, but regulates glucose transporter protein and insulin signal transduction, regulates glycogen synthesis and elevates cellular O-glycosylation levels, stimulates cytokines, etc.

38The sorbitol/polyol pathway is similarly increased in the high glucose state, where sorbitol is, in turn, converted to fructose by sorbitol dehydrogenase (SDH), resulting in the production of 3-deoxyglucosone (3DG), a highly reactive α-oxo-aldehyde, and promoting the production of AGEs. AR is also a key enzyme in this pathway. AR promotes the conversion of glucose to sorbitol and further to fructose with the participation of NADPH (produced by the pentose phosphate pathway). In the hyperglycemic state, AR depletes NADPH while increasing the accumulation of F6P, so there is a close influence between several glucose metabolic pathways. Not only that, AR decreases glutathione levels and glutathione peroxidase activity, and reduces cellular antioxidant capacity through amino acid metabolism. Elevated intracellular sorbitol also provides excess nicotinamide adenine dinucleotide (NADH) to the mitochondrial electron transport chain, which is a substrate for complex I (substrate for complex I) in mitochondria and closely affects mitochondrial function and cellular energy metabolism. Overexpression of AR in mice increases susceptibility to diabetes-induced AS and ischemia/reperfusion injury., In contrast, aldose reductase inhibitors (ARIs) and AR gene-deficient animals have vascular protective effects in DPDs., Some natural compounds and plant extracts have shown the inhibitory effect of aldose reductase 2 (ALR2), which can improve inflammation and protect the vascular endothelium, but in recent years ARIs have not been successfully available for widespread clinical use.

Amino acid metabolism

39Amino acid metabolism plays an important role in diabetes and complications, and branched-chain amino acids may serve as new biomarkers as well as signaling pathways suggesting the risk of DPDs., Glutamine is a branched-chain amino acid that is synthesized by glutamine synthetase (GS) and hydrolyzed by glutaminase (GLS)., Glutamine levels were negatively associated with BMI and insulin resistance index (HOMA-IR) in men with type 2 diabetes. Glutamine in plasma binds the bridging protein GRB-10 and improves the insulin resistance of cells. It also promotes the secretion of GLP-1 and GLP-2 secretion from intestinal cells., Vascular EC expresses glutaminase (GLS) and break down glutamine, and glutamine deficiency or inhibition of endothelial GLS1 can cause impaired EC proliferation and reduced vascular neogenesis. Increased glutamine synthetase (GS) transcription or increased glutamine levels promote macrophage polarization and atherosclerotic plaque formation. Chromosome 1q25 single nucleotide polymorphism (SNP) variants cause reduced GS expression in EC. In these populations, patients with diabetes have an increased risk of CAD but not patients with diabetes, and the causal mechanism remains to be determined.

40Glutamine metabolism in cells holds two branches: glutamine catabolism and asparagine synthetase/gamma-aminobutyric acid (ASNS-GABA) shunting. These two pathways independently regulate the AMP-activated protein kinase/mechanistic target of the rapamycin kinase complex (AMPK/mTORC) pathway, mediating cellular autophagy., Also, glutamine provides anaplerotic substrates for the TCA cycle., In EC, 30% of the tricarboxylic acid carbon comes from glutamine, comparable to that produced by the glycolytic pathway, and the novel hypoglycemic agent SGLT-2i can regulate mitochondrial oxidative phosphorylation and improve cellular energy metabolism through the above pathway. Glutamine metabolites are involved in intracellular oxygen reduction regulation. EC produces glutathione via glutamine, which regulates redox homeostasis, and its depletion makes EC vulnerable to ROS-induced damage. Glutamine catabolism produces glutamate that is converted to ornithine and aspartate and these generated amino acids are also involved in the proliferation of EC. EC proliferation is reduced after silencing of asparagine synthetase (ASNS), and supplementation with asparagine and α-ketoglutarate reverses the EC damage caused by glutamine deficiency., Thus, asparagine is also an important part of amino acid metabolism in DPDs.

41Amino acid metabolism also affects oxidative stress in EC via the arginine metabolic pathway. Vascular protective NO is produced via endothelial-type nitric oxide synthase (eNOS)., In vitro experiments, arginine deficiency leads to EC eNOS dysfunction. Elevated arginase levels lead to L-arginine depletion, decreased output of NO, increased ROS, and impaired endothelium-dependent vasodilation. On the other hand, EC can absorb serine directly or produce serine in the reaction intermediate 3-phosphoglycerate of the glycolytic pathway for nucleotide biosynthesis and redox homeostasis. The serine pathway is activated in the high glucose state and it synergizes with the pentose phosphate pathway with single carbon metabolism to alter chromatin status and promote inflammation.

Fatty acid metabolism

42Diabetic patients often have abnormal lipid metabolism, and hyperlipidemia can lead to increased cellular uptake of fatty acids through passive diffusion and protein-mediated pathways. A cluster of differentiation 36 (CD36) and the fatty acid binding protein (FABP) family mediate fatty acid uptake into tissues, and soluble CD36 expression is increased in diabetic patients. Fatty acid uptake and transport by EC is extremely important for many cellular processes, including membrane synthesis, intracellular signaling, ATP production, and post-translational modification of proteins. Imbalance of fatty acid metabolism in EC does not lead to significant abnormalities in energy supply or disturbance of redox homeostasis, but can impair de novo nucleotide synthesis for DNA replication. For example, DNA repair factors such as Polyadp-ribose polymerase (PARP) are involved in fatty acid metabolism. In a high glucose state, vascular damage can be aggravated by PARP1.

43Fatty acid metabolism plays an important role in high-energy-demand cells and is closely associated with diabetic heart disease in DPDs., Overexpression of GLUT-1 in the myocardium increased glucose levels in cardiomyocytes and revealed that FAO in the heart was inhibited and that a high fatty acid diet failed to upregulate FAO in these hearts, while glucose supply was significantly increased, further leading to activation of p38 mitogen-activated protein kinase and increased oxidative stress in the heart.

Mitochondrial dysfunction

44An imbalance in energy metabolic pathways causes impaired mitochondrial function, most often manifested as increased mitochondrial autophagy and ROS production. Mitochondrial function plays an important role in cellular energy homeostasis. Alterations in glycolytic pathways, fatty acid oxidation, and some amino acid metabolism in the high glucose state can affect mitochondrial oxidative phosphorylation processes. AGEs production in the hyperglycemic state and AGE-RAGE-induced increase in cytoplasmic ROS promote the production of mitochondrial superoxide and the development of diabetic microangiopathy in the condition of hyperglycemia., Most ROS are derived from complexes I and III in mitochondria. In addition to complexes I and III, the NOX family also promotes the mitochondrial production of ROS., NOX4 is the highest expressed member of the NOX family and is upregulated by a variety of agonizts and cellular stress., Administration of novel mitochondria-targeted drugs helps to improve the mitochondrial ROS/NLRP3 axis and attenuate mesangial tubular injury in DKD; similar manifestations exist in the myocardium, attenuating diabetic myocardial ischemia-reperfusion injury68. The intramitochondrial protein p66Shc can promote increased reactive oxygen species in mitochondria by interfering with Ras activation or binding to cytochrome C and other.

45Mitochondria can store calcium ions and act in concert with the endoplasmic reticulum and extracellular matrix to control the dynamic balance of calcium ion concentration in cells and regulate the cell cycle and apoptosis. High glucose can affect myocardial contractile function by upregulating sarcolipin (SLN) promotes calcium sparks. Therapeutically, metformin inhibits mitochondrial respiratory chain complex-1 and regulates cellular energy metabolism. In addition, metformin and GLP-1 agonizts regulate the glucagon-lowering hormone glucagon-like peptide-1 and the bile acid pathway and alter the composition of the gut microbiota, which may also indirectly affect mitochondrial function.,

46Mitochondrial energy metabolism differs among target organs, and myocardial mitochondrial content is abundant. Diabetic mice have altered mitochondrial function in the myocardium earlier than in the kidney, brain, and liver. Further in-depth mechanistic exploration is worthwhile in tissues with high mitochondrial content.

Insulin resistance

47Insulin resistance is the most common and widespread molecular mechanism of diabetic complications, not only in the high glucose state with extensive activation of insulin receptor signaling pathways, such as the regulation of glucose uptake by GLUT. Even in the presence of normal blood glucose, insulin resistance is still harmful, and the lack of insulin receptor signaling pathways in renal pedal cells induces a disease state similar to diabetic nephropathy.

48The most common downstream mechanisms of insulin resistance include inhibitory phosphorylation of IRS, growth factor receptor binding protein-2 (GRB-2), GRB-10, SHC transforming protein (SHC), and SH2B adapter protein-2 (SH2B-2) through induced insulin receptor., Selective glucose transporters exist in different target organs, such as the renal SGLT2 receptor; the distribution of GLUT receptors in different target organs and the pathways also differ., This paper summarizes the new advances in insulin signaling receptor pathways and their roles from 2018 to date (Table 4).

Glycosylation end-products

49As the end-products of dysfunctional EC metabolism, AGEs have profound effects on the immediate extracellular environment of EC as well as on other cell types. AGEs can bind key proteins (such as laminin, elastin, and collagen) in the extracellular matrix (ECM) basement membrane, leading to increased vascular stiffness promoting DPDs.– AGEs may also affect coagulation and hemodynamics, cause increased vascular permeability and induce tissue factor expression., The extensive intracellular action of circulating AGEs is mediated through the attachment of receptors for RAGE, which is expressed in monocytes, smooth muscle cells (SMC), and EC.,

50RAGE induces an inflammatory cascade response by activating the transcription factor NF-κB, which promotes the expression of growth factors and adhesion molecules. On the other hand, RAGE activates NADPH oxidase to increase oxidative stress; RAGE also binds to tissue-specific proteins to promote local vascular injury,, such as binding AGEs or S100/calmodulin or β-amyloid peptide to exacerbate cerebral hemorrhage; RAGE binds to EC to promote increased NADPH expression leading to inflammatory responses and a prothrombotic state by activating diaphanous-related 1 (DIAPH 1), ERK1, ERK2, and PKC., AGE/RAGE on mononuclear macrophages increases CD36 expression, promotes OX-LDL uptake while decreasing high-density lipoprotein (HDL) efflux, and promotes foam cell formation; AGE/RAGE action on vascular smooth muscle cells (VSMC) induces autophagy through the ERK/Akt pathway and increases ROS and NOS levels through activation of NOX and NF-κB,, increases oxidative stress, and accelerates atherosclerotic plaque progression. Excessive AGE formation and overactivation of the hexosamine pathway induce angiopoietin-2 transcription by inhibiting transcriptional co-repressor complex binding and silencing the angiopoietin-2 promoter. The formation of AGEs may partially explain the “hyperglycemic memory” of tissue damage, i.e., the vascular damage that occurs during hyperglycemia can continue into the normoglycemic cycle. Hyperglycemia may alter cellular epigenetics, such as DNA and protein modifications, DNA methylation, non-coding RNA, or histone modifications by receptor-mediated mechanisms to alter cellular function. Thus, epigenetics, as well as AGEs, are important targets for intervention outside of glycemic control.

Prospects

51DPD has become a major public health problem that requires urgent attention, as 11% of patients with T2DM complicated with AS have a multivessel disease. Patients with T2DM complicated with the multivessel disease have a significantly higher risk of ischemic events and overall mortality than those with T2DM with single-vessel disease. The significant cardio-renal benefits of metformin and SGLT-2i beyond glycemic control have led to the emergence of an integrated treatment model that can be applied to manage DPD. The pathogenesis of DPD involves insulin resistance, inflammation, oxidative stress, and AGEs, with a wide prevalence of hyperglycemic “metabolic memory” and some epigenetic alterations in various vascular pathologies., The latest drugs in development are ARIs, tyrosine phosphatase 1B inhibitors, PPAR-γ agonizts, regulators of the glucagon system, and mitochondrial energy modulators. Antisense oligonucleotides and monoclonal antibodies are widely developed., New biomarkers and drug intervention targets to improve the prognosis of DPD hold enormous potential for clinical applications.

52Diabetic microangiopathy and macroangiopathy significantly differ, and simultaneously developing them in animal models is challenging. However, clinical practice has often found coexisting interactive macroangiopathy and microangiopathy. The predictive relationship among DPDs also suggests that diabetic microangiopathy is not the only indicator of the risk for macroangiopathy, and that the various types of diabetic microangiopathy are also closely interrelated. In recent years, several molecular pathways with simultaneously large/microvascular protective effects have been identified (PPAR-γ, CXCR4, etc.), but most of them are still in animal experiments or phase I clinical stage.

53DPD research also faces several challenges. Concepts should be integrated across disciplines that focus on specific aspects of DM and angiopathy management in different organs. Research results of new technology might be redundant. For example, miRNA-based studies of diagnosis or regulation have found that miR-21 plays an important role in diabetic vascular complications;,,– however, the role of miR-21 in organs and at various points during disease progression remains unknown because concepts across disciplines have not been fully integrated. New technologies such as induced pluripotent stem cells should be developed to enrich experimental findings of DPD and construct model human blood vessel organoids. Multi-omic studies, should explore the pathogenesis of DPD. Furthermore, new cross-disciplinary, integrated prevention and treatment models should also be developed. Cross-collaborations among medical and research institutions and academic organizations are needed to narrow gaps among research results, new technologies, and clinical applications. Cross-collaborations among medical institutions at all levels are needed to fully integrate the resources of primary- and higher-level care. Cross-collaborations among doctors, nursing staff, and patients are needed to ensure personalized treatment for patients. Cross-collaborations among clinical disciplines, including endocrinology, cardiovasology, geriatrics, neurology, nephrology, vascular surgery, and nutrition are also needed to integrate comprehensive evidence. Traditional Chinese medicine also has considerable potential for the prevention and treatment of DPD., A comprehensive DPD prevention and treatment system should be established with Chinese characteristics, promoted cooperation, and accelerated clinical translation to improve the overall prevention and control of chronic diseases such as diabetes.

References 529

1.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pr. 2010;87:4-14.
Not in our library10.1016/j.diabres.2009.10.007
2.
Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62:3-16.
Not in our library10.1007/s00125-018-4711-2
3.
Jia W, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab. Res. Rev. 2019;35:e3158.
Not in our library10.1002/dmrr.3158
4.
Bruno G, et al. Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy. Diabetes Care. 2005;28:2613-2619.
Not in our library10.2337/diacare.28.11.2613
5.
Avogaro A, Fadini GP. Microvascular complications in diabetes: a growing concern for cardiologists. Int J. Cardiol. 2019;291:29-35.
Not in our library10.1016/j.ijcard.2019.02.030
6.
Hypoxia and hypoxia-inducible factors in diabetes and its complications · 2021
No notice
7.
Emerging Targets in Type 2 Diabetes and Diabetic Complications · 2021
No notice
8.
Kaplovitch E, et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol. 2021;6:21-29.
Not in our library10.1001/jamacardio.2020.4390
9.
Zhou, X., Yu, L., Zhao, Y. & Ge, J. Panvascular medicine: an emerging discipline focusing on atherosclerotic diseases. Eur. Heart. J. 43, 4528–4531 (2022).
Not in our library10.1093/eurheartj/ehac448
10.
Dal Canto E, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur. J. Prev. Cardiol. 2019;26:25-32.
Not in our library10.1177/2047487319878371
11.
Sandoval-Garcia E, et al. Retinal arteriolar tortuosity and fractal dimension are associated with long-term cardiovascular outcomes in people with type 2 diabetes. Diabetologia. 2021;64:2215-2227.
Not in our library10.1007/s00125-021-05499-z
12.
Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog. Cardiovasc. Dis. 2019;62:298-302.
Not in our library10.1016/j.pcad.2019.07.003
13.
Kotte AN, van Leeuwen GM, Lagendijk JJ. Modelling the thermal impact of a discrete vessel tree. Phys. Med. Biol. 1999;44:57-74.
Not in our library10.1088/0031-9155/44/1/006
14.
van Kuijk JP, et al. Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease. Eur. Heart J. 2010;31:992-999.
Not in our library10.1093/eurheartj/ehp553
15.
Jacob M, Chappell D, Becker BF. Regulation of blood flow and volume exchange across the microcirculation. Crit. Care. 2016;20:319.
Not in our library10.1186/s13054-016-1485-0
16.
Freeman K, Tao W, Sun H, Soonpaa MH, Rubart M. In situ three-dimensional reconstruction of mouse heart sympathetic innervation by two-photon excitation fluorescence imaging. J. Neurosci. Methods. 2014;221:48-61.
Not in our library10.1016/j.jneumeth.2013.09.005
17.
Polovina M, et al. Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation. Eur. J. Heart Fail. 2020;22:113-125.
Not in our library10.1002/ejhf.1666
18.
Kozakova M, Morizzo C, Fraser AG, Palombo C. Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus. Cardiovasc. Diabetol. 2017;16:78.
Not in our library10.1186/s12933-017-0557-z
19.
Grubić Rotkvić P, et al. The mystery of diabetic cardiomyopathy: from early concepts and underlying mechanisms to novel therapeutic possibilities. Int. J. Mol. Sci. 2021;22:5973.
Not in our library10.3390/ijms22115973
20.
Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61:21-28.
Not in our library10.1007/s00125-017-4390-4
21.
Xu L, Yan X, Tang Z, Feng B. Association between circulating oxidized OxLDL/LDL-C ratio and the severity of coronary atherosclerosis, along with other emerging biomarkers of cardiovascular disease in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2022;191:110040.
Not in our library10.1016/j.diabres.2022.110040
22.
Gordin D, et al. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2014;37:2593-2600.
Not in our library10.2337/dc14-0065
23.
Platt DE, et al. Type II diabetes mellitus and hyperhomocysteinemia: a complex interaction. Diabetol. Metab. Syndr. 2017;9:19.
Not in our library10.1186/s13098-017-0218-0
24.
Hu T, et al. Plasma fingerprint of free fatty acids and their correlations with the traditional cardiac biomarkers in patients with type 2 diabetes complicated by coronary heart disease. Front. Cardiovasc. Med. 2022;9:903412.
Not in our library10.3389/fcvm.2022.903412
25.
Kobiyama K, Ley K. Atherosclerosis. Circ. Res. 2018;123:1118-1120.
Not in our library10.1161/circresaha.118.313816
26.
Kimura T, et al. Regulatory CD4(+) T cells recognize major histocompatibility complex class II molecule-restricted peptide epitopes of apolipoprotein B. Circulation. 2018;138:1130-1143.
Not in our library10.1161/circulationaha.117.031420
27.
Sherer Y, et al. Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis. Ann. N. Y Acad. Sci. 2007;1108:259-267.
Not in our library10.1196/annals.1422.028
28.
Govea-Alonso DO, Beltrán-López J, Salazar-González JA, Vargas-Morales J, Rosales-Mendoza S. Progress and future opportunities in the development of vaccines against atherosclerosis. Expert Rev. Vaccines. 2017;16:337-350.
Not in our library10.1080/14760584.2017.1258309
29.
Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ. Res. 2019;124:121-141.
Not in our library10.1161/circresaha.118.311371
30.
Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat. Rev. Endocrinol. 2016;12:144-153.
Not in our library10.1038/nrendo.2015.216
31.
Lin K-H, et al. Carboxyl terminus of HSP70-interacting protein attenuates advanced glycation end products-induced cardiac injuries by promoting NFκB proteasomal degradation. J. Cell. Physiol. 2022;237:1888-1901.
Not in our library10.1002/jcp.30660
32.
Su S-C, et al. Cilostazol inhibits hyperglucose-induced vascular smooth muscle cell dysfunction by modulating the RAGE/ERK/NF-κB signaling pathways. J. Biomed. Sci. 2019;26:68.
Not in our library10.1186/s12929-019-0550-9
33.
MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy · 2020
No notice
34.
Yang Y-C, et al. Pkcδ activation is involved in ROS-mediated mitochondrial dysfunction and apoptosis in cardiomyocytes exposed to advanced glycation end products (Ages). Aging Dis. 2018;9:647-663.
Not in our library10.14336/ad.2017.0924
35.
Hussain S, et al. Hyperglycemia induces myocardial dysfunction via epigenetic regulation of JunD. Circ. Res. 2020;127:1261-1273.
Not in our library10.1161/circresaha.120.317132
36.
Zhang Q, et al. LncDACH1 promotes mitochondrial oxidative stress of cardiomyocytes by interacting with sirtuin3 and aggravates diabetic cardiomyopathy. Sci. China Life Sci. 2022;65:1198-1212.
Not in our library10.1007/s11427-021-1982-8
37.
Kizub IV, Pavlova OO, Johnson CD, Soloviev AI, Zholos AV. Rho kinase and protein kinase C involvement in vascular smooth muscle myofilament calcium sensitization in arteries from diabetic rats. Br. J. Pharmacol. 2010;159:1724-1731.
Not in our library10.1111/j.1476-5381.2010.00666.x
38.
Kizub IV, Klymenko KI, Soloviev AI. Protein kinase C in enhanced vascular tone in diabetes mellitus. Int. J. Cardiol. 2014;174:230-242.
Not in our library10.1016/j.ijcard.2014.04.117
39.
Li G, et al. Syringaresinol protects against type 1 diabetic cardiomyopathy by alleviating inflammation responses, cardiac fibrosis, and oxidative stress. Mol. Nutr. Food Res. 2020;64:e2000231.
Not in our library10.1002/mnfr.202000231
40.
García-Díez E, et al. Supplementation with a cocoa-carob blend, alone or in combination with metformin, attenuates diabetic cardiomyopathy, cardiac oxidative stress and inflammation in Zucker diabetic rats. Antioxidants. 2022;11:432.
Not in our library10.3390/antiox11020432
41.
Song S, et al. Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation. Acta Pharmacol. Sin. 2021;42:230-241.
Not in our library10.1038/s41401-020-0490-7
42.
Rajagopalan S, Brook R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017;377:2098-2099.
Not in our library10.1056/nejmc1712572
43.
Jorsal A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur. J. Heart Fail. 2017;19:69-77.
Not in our library10.1002/ejhf.657
44.
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2016;375:1834-1844.
Not in our library10.1056/nejmoa1607141
45.
Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013;369:1317-1326.
Not in our library10.1056/nejmoa1307684
46.
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64-74.
Not in our library10.1016/s1474-4422(05)70284-2
47.
Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia. 2009;52:1031-1039.
Not in our library10.1007/s00125-009-1323-x
48.
Xue M, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. Ageing Res. Rev. 2019;55:100944.
Not in our library10.1016/j.arr.2019.100944
49.
van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer CDA. Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol. 2020;8:325-336.
Not in our library10.1016/s2213-8587(19)30405-x
50.
Crane PK, et al. Glucose levels and risk of dementia. N. Engl. J. Med. 2013;369:540-548.
Not in our library10.1056/nejmoa1215740
51.
Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur. J. Pharm. 2008;585:97-108.
Not in our library10.1016/j.ejphar.2008.02.049
52.
Jellinger KA. Pathomechanisms of vascular depression in older adults. Int. J. Mol. Sci. 2021;23:308.
Not in our library10.3390/ijms23010308
53.
Cannistraro RJ, et al. CNS small vessel disease: a clinical review. Neurology. 2019;92:1146-1156.
Not in our library10.1212/wnl.0000000000007654
54.
Masi S, et al. Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. Eur. Heart J. 2021;42:2590-2604.
Not in our library10.1093/eurheartj/ehaa857
55.
Animal Models of Chronic Cerebral Hypoperfusion: From Mouse to Primate · 2019
No notice
56.
Lin MP, et al. Collateral recruitment is impaired by cerebral small vessel disease. Stroke. 2020;51:1404-1410.
Not in our library10.1161/strokeaha.119.027661
57.
Shi L, et al. Mapping the contribution and strategic distribution patterns of neuroimaging features of small vessel disease in poststroke cognitive impairment. J. Neurol. Neurosurg. Psychiatry. 2018;89:918-926.
Not in our library10.1136/jnnp-2017-317817
58.
Kim GM, et al. Extensive leukoaraiosis is associated with high early risk of recurrence after ischemic stroke. Stroke. 2014;45:479-485.
Not in our library10.1161/strokeaha.113.003004
59.
Wei C, et al. Cerebral small vessel disease combined with cerebral collaterals to predict the prognosis of patients with acute large artery atherosclerotic stroke. Front. Neurol. 2022;13:969637.
Not in our library10.3389/fneur.2022.969637
60.
Zhou JY, et al. Beyond collaterals: brain frailty additionally improves prediction of clinical outcome in acute ischemic stroke. Eur. Radio. 2022;32:6943-6952.
Not in our library10.1007/s00330-022-08792-6
61.
Ryu WS, et al. Stroke outcomes are worse with larger leukoaraiosis volumes. Brain. 2017;140:158-170.
Not in our library10.1093/brain/aww259
62.
Tsukuda K, et al. Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine. Hypertension. 2008;51:528-533.
Not in our library10.1161/hypertensionaha.107.101634
63.
Khandelwal M, Manglani K, Upadhyay P, Azad M, Gupta S. AdipoRon induces AMPK activation and ameliorates Alzheimer’s like pathologies and associated cognitive impairment in APP/PS1 mice. Neurobiol. Dis. 2022;174:105876.
Not in our library10.1016/j.nbd.2022.105876
64.
Prabhakar NR, Peng YJ, Nanduri J. Hypoxia-inducible factors and obstructive sleep apnea. J. Clin. Invest. 2020;130:5042-5051.
Not in our library10.1172/jci137560
65.
Reijmer YD, Leemans A, Brundel M, Kappelle LJ, Biessels GJ. Disruption of the cerebral white matter network is related to slowing of information processing speed in patients with type 2 diabetes. Diabetes. 2013;62:2112-2115.
Not in our library10.2337/db12-1644
66.
Zhang J, et al. Disrupted white matter network and cognitive decline in type 2 diabetes patients. J. Alzheimers Dis. 2016;53:185-195.
Not in our library10.3233/jad-160111
67.
Impaired cerebral blood flow in type 2 diabetes mellitus – A comparative study with subjective cognitive decline, vascular dementia and Alzheimer’s disease subjects · 2020
Not checked
68.
Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron. 2017;96:17-42.
Not in our library10.1016/j.neuron.2017.07.030
69.
Blevins BL, et al. Brain arteriolosclerosis. Acta Neuropathol. 2021;141:1-24.
Not in our library10.1007/s00401-020-02235-6
70.
Zhang J, et al. White matter integrity disruptions associated with cognitive impairments in type 2 diabetic patients. Diabetes. 2014;63:3596-3605.
Not in our library10.2337/db14-0342
71.
Zhou X, et al. Aggravated cognitive and brain functional impairment in mild cognitive impairment patients with type 2 diabetes: a resting-state functional MRI study. J. Alzheimers Dis. 2014;41:925-935.
Not in our library10.3233/jad-132354
72.
Gurol ME. Atrial fibrillation and FLAIR/T2 white matter hyperintensities on MRI. J. Neurol. Neurosurg. Psychiatry. 2018;89:1-2.
Not in our library10.1136/jnnp-2017-316290
73.
Villano A, et al. Endothelial dysfunction and cardiovascular outcome in asymptomatic patients with type 2 diabetes: a pilot study. Diabetes Metab. Res. Rev. 2020;36:e3215.
Not in our library10.1002/dmrr.3215
74.
Rom S, et al. Hyperglycemia-driven neuroinflammation compromises BBB leading to memory loss in both diabetes mellitus (DM) type 1 and type 2 mouse models. Mol. Neurobiol. 2019;56:1883-1896.
Not in our library10.1007/s12035-018-1195-5
75.
Yu H, et al. Platelet biomarkers identifying mild cognitive impairment in type 2 diabetes patients. Aging Cell. 2021;20:e13469.
Not in our library10.1111/acel.13469
76.
Bogush M, Heldt NA, Persidsky Y. Blood brain barrier injury in diabetes: unrecognized effects on brain and cognition. J. Neuroimmune Pharm. 2017;12:593-601.
Not in our library10.1007/s11481-017-9752-7
77.
Wing RR, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 2013;369:145-154.
Not in our library10.1056/nejmoa1212914
78.
Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharm. Ther. 2012;136:82-93.
Not in our library10.1016/j.pharmthera.2012.07.006
79.
Fernandez AM, et al. Insulin regulates neurovascular coupling through astrocytes. Proc. Natl Acad. Sci. USA. 2022;119:e2204527119.
Not in our library10.1073/pnas.2204527119
80.
Pan W, Kastin AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology. 2000;72:171-178.
Not in our library10.1159/000054584
81.
Geijselaers SLC, Sep SJS, Stehouwer CDA, Biessels GJ. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. Lancet Diabetes Endocrinol. 2015;3:75-89.
Not in our library10.1016/s2213-8587(14)70148-2
82.
Exalto LG, et al. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol. 2013;1:183-190.
Not in our library10.1016/s2213-8587(13)70048-2
83.
Huang YK, et al. The role of aldose reductase in beta-amyloid-induced microglia activation. Int. J. Mol. Sci. 2022;23:15088.
Not in our library10.3390/ijms232315088
84.
Baum P, Toyka KV, Blüher M, Kosacka J, Nowicki M. Inflammatory mechanisms in the pathophysiology of diabetic peripheral neuropathy (DN)-new aspects. Int. J. Mol. Sci. 2021;22:10835.
Not in our library10.3390/ijms221910835
85.
Cantini G, Mannucci E, Luconi M. Perspectives in GLP-1 research: new targets, new receptors. Trends Endocrinol. Metab. 2016;27:427-438.
Not in our library10.1016/j.tem.2016.03.017
86.
Talbot K, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012;122:1316-1338.
Not in our library10.1172/jci59903
87.
Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat. Rev. Mol. Cell Biol. 2018;19:31-44.
Not in our library10.1038/nrm.2017.89
88.
Cui Y, et al. Melatonin prevents diabetes-associated cognitive dysfunction from microglia-mediated neuroinflammation by activating autophagy via TLR4/Akt/mTOR pathway. FASEB J. 2021;35:e21485.
Not in our library10.1096/fj.202002247rr
89.
Gu HF, et al. Nicotinate-curcumin ameliorates cognitive impairment in diabetic rats by rescuing autophagic flux in CA1 hippocampus. CNS Neurosci. Ther. 2019;25:430-441.
Not in our library10.1111/cns.13059
90.
Mohamed MAE, Abdel-Rahman RF, Mahmoud SS, Khattab MM, Safar MM. Metformin and trimetazidine ameliorate diabetes-induced cognitive impediment in status epileptic rats. Epilepsy Behav. 2020;104:106893.
Not in our library10.1016/j.yebeh.2019.106893
91.
Rizzo MR, et al. Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment. Pharm. Res. 2022;176:106062.
Not in our library10.1016/j.phrs.2022.106062
92.
Tian J, et al. Ginkgo biloba leaf extract attenuates atherosclerosis in streptozotocin-induced diabetic ApoE-/- mice by inhibiting endoplasmic reticulum stress via restoration of autophagy through the mTOR signaling pathway. Oxid. Med. Cell Longev. 2019;2019:8134678.
Not in our library10.1155/2019/8134678
93.
Kong FJ, et al. Endoplasmic reticulum stress/autophagy pathway is involved in diabetes-induced neuronal apoptosis and cognitive decline in mice. Clin. Sci. 2018;132:111-125.
Not in our library10.1042/cs20171432
94.
Liu Y, Weng W, Gao R, Liu Y. New insights for cellular and molecular mechanisms of aging and aging-related diseases: herbal medicine as potential therapeutic approach. Oxid. Med. Cell Longev. 2019;2019:4598167.
Not in our library10.1155/2019/4598167
95.
Natunen T, et al. Diabetic phenotype in mouse and humans reduces the number of microglia around β-amyloid plaques. Mol. Neurodegener. 2020;15:66.
Not in our library10.1186/s13024-020-00415-2
96.
Tian J, et al. Interplay between exosomes and autophagy in cardiovascular diseases: novel promising target for diagnostic and therapeutic application. Aging Dis. 2019;10:1302-1310.
Not in our library10.14336/ad.2018.1020
97.
Dybjer E, et al. Incretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a population-based study. Diabet. Med. 2020;37:1157-1166.
Not in our library10.1111/dme.14267
98.
Design and Feasibility of a Randomized Controlled Pilot Trial to Reduce Exposure and Cognitive Risk Associated With Advanced Glycation End Products in Older Adults With Type 2 Diabetes · 2021
Not checked
99.
Rom S, et al. Hyperglycemia and advanced glycation end products disrupt BBB and promote occludin and claudin-5 protein secretion on extracellular microvesicles. Sci. Rep. 2020;10:7274.
Not in our library10.1038/s41598-020-64349-x
100.
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF) · 2021
No notice
101.
Toyama K, et al. Apoptosis signal-regulating kinase 1 is a novel target molecule for cognitive impairment induced by chronic cerebral hypoperfusion. Arterioscler. Thromb. Vasc. Biol. 2014;34:616-625.
Not in our library10.1161/atvbaha.113.302440
102.
Tang SS, et al. ERα and/or ERβ activation ameliorates cognitive impairment, neurogenesis and apoptosis in type 2 diabetes mellitus mice. Exp. Neurol. 2019;311:33-43.
Not in our library10.1016/j.expneurol.2018.09.002
103.
Wei TH, Hsieh CL. Effect of acupuncture on the p38 signaling pathway in several nervous system diseases: a systematic review. Int. J. Mol. Sci. 2020;21:4693.
Not in our library10.3390/ijms21134693
104.
Zhang J, et al. TREM-2-p38 MAPK signaling regulates neuroinflammation during chronic cerebral hypoperfusion combined with diabetes mellitus. J. Neuroinflammation. 2020;17:2.
Not in our library10.1186/s12974-019-1688-9
105.
Endoplasmic Reticulum Stress and Associated ROS · 2016
No notice
106.
Otter S, Lammert E. Exciting times for pancreatic islets: glutamate signaling in endocrinecells. Trends Endocrinol. Metab. 2016;27:177-188.
Not in our library10.1016/j.tem.2015.12.004
107.
Li Y, et al. Treatment of cerebral ischemia through NMDA receptors: metabotropic signaling and future directions. Front. Pharm. 2022;13:831181.
Not in our library10.3389/fphar.2022.831181
108.
Grzeda E, Wiśniewska RJ, Wiśniewski K. Effect of an NMDA receptor agonist on T-maze and passive avoidance test in 12-week streptozotocin-induced diabetic rats. Pharm. Rep. 2007;59:656-663.
Not in our library
109.
Bath PM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int. J. Stroke. 2015;10:469-478.
Not in our library10.1111/ijs.12466
110.
Patrone C, Eriksson O, Lindholm D. Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol. 2014;2:256-262.
Not in our library10.1016/s2213-8587(13)70125-6
111.
Orkaby AR, Cho K, Cormack J, Gagnon DR, Driver JA. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. Neurology. 2017;89:1877-1885.
Not in our library10.1212/wnl.0000000000004586
112.
Areosa Sastre A, Vernooij RW, González-Colaço Harmand M, Martínez G. Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst. Rev. 2017;6:Cd003804.
Not in our library10.1002/14651858.cd003804.pub2
113.
de Galan BE, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia. 2009;52:2328-2336.
Not in our library10.1007/s00125-009-1484-7
114.
Haroon NN, et al. Risk of dementia in seniors with newly diagnosed diabetes: a population-based study. Diabetes Care. 2015;38:1868-1875.
Not in our library10.2337/dc15-0491
115.
The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke · 2019
No notice
116.
Luchsinger JA, et al. Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J. Alzheimers Dis. 2016;51:501-514.
Not in our library10.3233/jad-150493
117.
Samaras K, et al. Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney Memory and Ageing Study. Diabetes Care. 2020;43:2691-2701.
Not in our library10.2337/dc20-0892
118.
Kumar AP, et al. Glitazones, PPAR-γ and neuroprotection. Mini Rev. Med. Chem. 2021;21:1457-1464.
Not in our library10.2174/1389557521666210304112403
119.
Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast · 2022
No notice
120.
Palmer SC, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573.
Not in our library10.1136/bmj.m4573
121.
Zannad F, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet. 2020;396:819-829.
Not in our library10.1016/s0140-6736(20)31824-9
122.
Zhou Z, et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke. 2021;52:1545-1556.
Not in our library10.1161/strokeaha.120.031623
123.
Khanna A, Walcott BP, Kahle KT, Simard JM. Effect of glibenclamide on the prevention of secondary brain injury following ischemic stroke in humans. Neurosurg. Focus. 2014;36:E11.
Not in our library10.3171/2013.10.focus13404
124.
Vorasayan P, et al. Intravenous glibenclamide reduces lesional water uptake in large hemispheric infarction. Stroke. 2019;50:3021-3027.
Not in our library10.1161/strokeaha.119.026036
125.
Wada T, et al. Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions. Eur. J. Pharm. 2013;707:120-129.
Not in our library10.1016/j.ejphar.2013.03.016
126.
Hamed SA. Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications. Expert Rev. Clin. Pharm. 2017;10:409-428.
Not in our library10.1080/17512433.2017.1293521
127.
Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, Chrousos GP, Papassotiriou I. Biomarkers of diabetic nephropathy: a 2017 update. Crit. Rev. Clin. Lab Sci. 2017;54:326-342.
Not in our library10.1080/10408363.2017.1377682
128.
Global, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019 · 2021
No notice
129.
Wimmer RA, et al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature. 2019;565:505-510.
Not in our library10.1038/s41586-018-0858-8
130.
Pérez-Morales RE, et al. Inflammation in diabetic kidney disease. Nephron. 2019;143:12-16.
Not in our library10.1159/000493278
131.
Mora-Fernández, C. et al. Diabet. kidney disease: from physiology to therapeutics. J. Physiol. 592, 3997–4012 (2014).
Not in our library10.1113/jphysiol.2014.272328
132.
Carlstrom M, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease. Physiol. Rev. 2015;95:405-511.
Not in our library10.1152/physrev.00042.2012
133.
Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA. Renal microvascular dysfunction, hypertension and CKD progression. Curr. Opin. Nephrol. Hypertens. 2013;22:1-9.
Not in our library10.1097/mnh.0b013e32835b36c1
134.
Roman RJ, Fan F. Genetic susceptibility to hypertension-induced renal injury. Hypertension. 2018;71:559-560.
Not in our library10.1161/hypertensionaha.118.10773
135.
Balafa O, Kalaitzidis R, Siamopoulos KC. Optimal medical management in patients with renovascular hypertension. Am. J. Cardiovasc. Drugs. 2013;13:71-78.
Not in our library10.1007/s40256-013-0011-x
136.
Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur. Heart J. 2013;34:2436-2443.
Not in our library10.1093/eurheartj/eht149
137.
Neuen BL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845-854.
Not in our library10.1016/s2213-8587(19)30256-6
138.
Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017;377:2099.
Not in our library10.1056/nejmoa1611925
139.
Pan L, et al. Clinical significance of hemostatic parameters in the prediction for type 2 diabetes mellitus and diabetic nephropathy. Dis. Markers. 2018;2018:5214376.
Not in our library10.1155/2018/5214376
140.
Thomas MC, et al. Diabetic kidney disease. Nat. Rev. Dis. Prim. 2015;1:15018.
Not in our library10.1038/nrdp.2015.18
141.
Biomarkers of diabetic kidney disease · 2018
No notice
142.
Gohda T, et al. Clinical predictive biomarkers for normoalbuminuric diabetic kidney disease. Diabetes Res. Clin. Pr. 2018;141:62-68.
Not in our library10.1016/j.diabres.2018.04.026
143.
Liu JJ, et al. Vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1, is associated with diabetic kidney disease in Asians with type 2 diabetes. J. Diabetes Complications. 2015;29:707-712.
Not in our library10.1016/j.jdiacomp.2015.02.011
144.
Chauhan K, et al. Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes. Kidney Int. 2019;95:439-446.
Not in our library10.1016/j.kint.2018.09.019
145.
Noor T, et al. Relation of copeptin with diabetic and renal function markers among patients with diabetes mellitus progressing towards diabetic nephropathy. Arch. Med. Res. 2020;51:548-555.
Not in our library10.1016/j.arcmed.2020.05.018
146.
Coca SG, et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J. Am. Soc. Nephrol. 2017;28:2786-2793.
Not in our library10.1681/asn.2016101101
147.
Moresco RN, et al. Urinary kidney injury molecule-1 in renal disease. Clin. Chim. Acta. 2018;487:15-21.
Not in our library10.1016/j.cca.2018.09.011
148.
Wu L, et al. Associations of urinary epidermal growth factor and monocyte chemotactic protein-1 with kidney involvement in patients with diabetic kidney disease. Nephrol. Dial. Transpl. 2020;35:291-297.
Not in our library10.1093/ndt/gfy314
149.
Phanish MK, et al. Evaluation of urinary biomarkers of proximal tubular injury, inflammation, and fibrosis in patients with albuminuric and nonalbuminuric diabetic kidney disease. Kidney Int. Rep. 2021;6:1355-1367.
Not in our library10.1016/j.ekir.2021.01.012
150.
Lu Y, Liu D, Feng Q, Liu Z. Diabetic nephropathy: perspective on extracellular vesicles. Front. Immunol. 2020;11:943.
Not in our library10.3389/fimmu.2020.00943
151.
Kanakalakshmi ST, et al. Microparticles in diabetic kidney disease. Clin. Chim. Acta. 2022;531:418-425.
Not in our library10.1016/j.cca.2022.05.001
152.
Xu YX, et al. Exosomal ncRNAs: Novel therapeutic target and biomarker for diabetic complications. Pharm. Res. 2022;178:106135.
Not in our library10.1016/j.phrs.2022.106135
153.
Urinary small extracellular vesicles derived CCL21 mRNA as biomarker linked with pathogenesis for diabetic nephropathy · 2021
Not checked
154.
Hashemi E, et al. WT1 and ACE mRNAs of blood extracellular vesicle as biomarkers of diabetic nephropathy. J. Transl. Med. 2021;19:299.
Not in our library10.1186/s12967-021-02964-6
155.
Ding X, et al. A systematic review and Meta-analysis of urinary extracellular vesicles proteome in diabetic nephropathy. Front. Endocrinol. 2022;13:866252.
Not in our library10.3389/fendo.2022.866252
156.
Dubin RF, Rhee EP. Proteomics and metabolomics in kidney disease, including insights into etiology, treatment, and prevention. Clin. J. Am. Soc. Nephrol. 2020;15:404-411.
Not in our library10.2215/cjn.07420619
157.
Kato M, Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat. Rev. Nephrol. 2019;15:327-345.
Not in our library10.1038/s41581-019-0135-6
158.
Zhang Y, Zhang S, Wang G. Metabolomic biomarkers in diabetic kidney diseases-A systematic review. J. Diabetes Complications. 2015;29:1345-1351.
Not in our library10.1016/j.jdiacomp.2015.06.016
159.
Good DM, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell Proteom. 2010;9:2424-2437.
Not in our library10.1074/mcp.m110.001917
160.
CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis · 2013
No notice
161.
Raij L. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am. J. Hypertens. 2005;18:95S-99S.
Not in our library10.1016/j.amjhyper.2004.11.040
162.
Jeansson M, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J. Clin. Invest. 2011;121:2278-2289.
Not in our library10.1172/jci46322
163.
Sharma K, Cook A, Smith M, Valancius C, Inscho EW. TGF-beta impairs renal autoregulation via generation of ROS. Am. J. Physiol. Ren. Physiol. 2005;288:F1069-F1077.
Not in our library10.1152/ajprenal.00345.2004
164.
Yang W, et al. Ectopic lipid accumulation: potential role in tubular injury and inflammation in diabetic kidney disease. Clin. Sci. 2018;132:2407-2422.
Not in our library10.1042/cs20180702
165.
Fu Y, et al. Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism. Cell Metab. 2020;32:1052-1062 e1058.
Not in our library10.1016/j.cmet.2020.10.019
166.
Zafrani L, Ince C. Microcirculation in acute and chronic kidney diseases. Am. J. Kidney Dis. 2015;66:1083-1094.
Not in our library10.1053/j.ajkd.2015.06.019
167.
Kramann R, Wongboonsin J, Chang-Panesso M, Machado FG, Humphreys BD. Gli1(+) pericyte loss induces capillary rarefaction and proximal tubular injury. J. Am. Soc. Nephrol. 2017;28:776-784.
Not in our library10.1681/asn.2016030297
168.
Dimke H, et al. Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney. J. Am. Soc. Nephrol. 2015;26:1027-1038.
Not in our library10.1681/asn.2014010060
169.
Hakroush S, et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am. J. Pathol. 2009;175:1883-1895.
Not in our library10.2353/ajpath.2009.080792
170.
Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 2008;19:433-442.
Not in our library10.1681/asn.2007091048
171.
Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am. J. Physiol. Ren. Physiol. 2017;312:F716-F731.
Not in our library10.1152/ajprenal.00314.2016
172.
Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat. Rev. Nephrol. 2018;14:361-377.
Not in our library10.1038/s41581-018-0001-y
173.
Boels MG, et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes. 2016;65:2429-2439.
Not in our library10.2337/db15-1413
174.
Jung CY, Yoo TH. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab. J. 2022;46:181-197.
Not in our library10.4093/dmj.2021.0329
175.
Agere SA, Kim EY, Akhtar N, Ahmed S. Syndecans in chronic inflammatory and autoimmune diseases: pathological insights and therapeutic opportunities. J. Cell Physiol. 2018;233:6346-6358.
Not in our library10.1002/jcp.26388
176.
Ke G, et al. Receptor activator of NF-kappaB mediates podocyte injury in diabetic nephropathy. Kidney Int. 2021;100:377-390.
Not in our library10.1016/j.kint.2021.04.036
177.
Wang H, et al. Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2/NF-kappaB pathway. Metabolism. 2021;119:154740.
Not in our library10.1016/j.metabol.2021.154740
178.
Nam JS, et al. The activation of NF-kappaB and AP-1 in peripheral blood mononuclear cells isolated from patients with diabetic nephropathy. Diabetes Res. Clin. Pr. 2008;81:25-32.
Not in our library10.1016/j.diabres.2008.01.032
179.
Zhang C, et al. Positive and negative regulatory effects of transcription factor activator protein 1 (AP1) on the expression of antimicrobial peptides in Macrobrachium nipponense. Fish. Shellfish Immunol. 2020;98:130-137.
Not in our library10.1016/j.fsi.2020.01.002
180.
Garcia-Garcia PM, Getino-Melian MA, Dominguez-Pimentel V, Navarro-Gonzalez JF. Inflammation in diabetic kidney disease. World J. Diabetes. 2014;5:431-443.
Not in our library10.4239/wjd.v5.i4.431
181.
Badve SV, et al. Effects of allopurinol on the progression of chronic kidney disease. N. Engl. J. Med. 2020;382:2504-2513.
Not in our library10.1056/nejmoa1915833
182.
Doria A, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N. Engl. J. Med. 2020;382:2493-2503.
Not in our library10.1056/nejmoa1916624
183.
Prattichizzo F, de Candia P, Ceriello A. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism. 2021;120:154799.
Not in our library10.1016/j.metabol.2021.154799
184.
Mottl AK, et al. Long-term effects of intensive glycemic and blood pressure control and fenofibrate use on kidney outcomes. Clin. J. Am. Soc. Nephrol. 2018;13:1693-1702.
Not in our library10.2215/cjn.06200518
185.
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772.
Not in our library10.1161/circulationaha.116.021887
186.
Kidokoro K, et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation. 2019;140:303-315.
Not in our library10.1161/circulationaha.118.037418
187.
Hesp AC, et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int. 2020;98:579-589.
Not in our library10.1016/j.kint.2020.02.041
188.
Zhang Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94:524-535.
Not in our library10.1016/j.kint.2018.05.002
189.
van Bommel EJM, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97:202-212.
Not in our library10.1016/j.kint.2019.09.013
190.
Tanaka T, Higashijima Y, Wada T, Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014;86:701-711.
Not in our library10.1038/ki.2014.236
191.
Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 2020;383:2219-2229.
Not in our library10.1056/nejmoa2025845
192.
Zhang Y, Sun X, Icli B, Feinberg MW. Emerging roles for microRNAs in diabetic microvascular disease: novel targets for therapy. Endocr. Rev. 2017;38:145-168.
Not in our library10.1210/er.2016-1122
193.
Täubel J, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur. Heart J. 2021;42:178-188.
Not in our library10.1093/eurheartj/ehaa898
194.
Oe Y, et al. Coagulation factor Xa and protease-activated receptor 2 as novel therapeutic targets for diabetic nephropathy. Arterioscler Thromb. Vasc. Biol. 2016;36:1525-1533.
Not in our library10.1161/atvbaha.116.307883
195.
Ungar L, et al. Stroke outcomes with vorapaxar versus placebo in patients with acute coronary syndromes: insights from the TRACER trial. J. Am. Heart Assoc. 2018;7:e009609.
Not in our library10.1161/jaha.118.009609
196.
Tuttle KR, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrol. Dial. Transpl. 2018;33:1950-1959.
Not in our library10.1093/ndt/gfx377
197.
de Zeeuw D, et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018;6:925-933.
Not in our library10.1016/s2213-8587(18)30289-4
198.
Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease · 2019
No notice
199.
Soleimani A, et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney Int. 2017;91:435-442.
Not in our library10.1016/j.kint.2016.09.040
200.
Li HB, et al. Faecalibacterium prausnitzii attenuates CKD via butyrate-renal GPR43 axis. Circ. Res. 2022;131:e120-e134.
Not in our library10.1161/circresaha.122.320184
201.
Zhao J, et al. Efficacy of combined abelmoschus manihot and irbesartan for reduction of albuminuria in patients with type 2 diabetes and diabetic kidney disease: a multicenter randomized double-blind parallel controlled clinical trial. Diabetes Care. 2022;45:e113-e115.
Not in our library10.2337/dc22-0607
202.
Das T, et al. Recently updated global diabetic retinopathy screening guidelines: commonalities, differences, and future possibilities. Eye. 2021;35:2685-2698.
Not in our library10.1038/s41433-021-01572-4
203.
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-136.
Not in our library10.1016/s0140-6736(09)62124-3
204.
Diabetic Retinopathy: Pathophysiology and Treatments · 2018
No notice
205.
Khansari MM, et al. Automated deformation-based analysis of 3D optical coherence tomography in diabetic retinopathy. IEEE Trans. Med. Imaging. 2020;39:236-245.
Not in our library10.1109/tmi.2019.2924452
206.
Musch DC, Chew EY. Evidence for step therapy in diabetic macular edema. N. Engl. J. Med. 2022;387:751-752.
Not in our library10.1056/nejme2208454
207.
Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vis. Res. 2017;139:7-14.
Not in our library10.1016/j.visres.2017.04.003
208.
Elsherbiny NM, et al. Homocysteine induces inflammation in retina and brain. Biomolecules. 2020;10:393.
Not in our library10.3390/biom10030393
209.
Fickweiler W, et al. Elevated retinol binding protein 3 concentrations are associated with decreased vitreous inflammatory cytokines, VEGF, and progression of diabetic retinopathy. Diabetes Care. 2022;45:2159-2162.
Not in our library10.2337/dc22-0165
210.
Yokomizo H, et al. Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. Sci. Transl. Med. 2019;11:eaau6627.
Not in our library10.1126/scitranslmed.aau6627
211.
Helal HG, Rashed MH, Abdullah OA, Salem TI, Daifalla A. MicroRNAs (-146a, -21 and -34a) are diagnostic and prognostic biomarkers for diabetic retinopathy. Biomed. J. 2021;44:S242-S251.
Not in our library10.1016/j.bj.2020.11.003
212.
Hwang SJ, et al. miR-125a-5p attenuates macrophage-mediated vascular dysfunction by targeting Ninjurin1. Cell Death Differ. 2022;29:1199-1210.
Not in our library10.1038/s41418-021-00911-y
213.
Xie Q, et al. An innovative method for screening and evaluating the degree of diabetic retinopathy and drug treatment based on artificial intelligence algorithms. Pharmacol. Res. 2020;159:104986.
Not in our library10.1016/j.phrs.2020.104986
214.
Liu Y, et al. Monosodium glutamate-induced mouse model with unique diabetic retinal neuropathy features and artificial intelligence techniques for quantitative evaluation. Front. Immunol. 2022;13:862702.
Not in our library10.3389/fimmu.2022.862702
215.
Jiang H, Zhang H, Jiang X, Wu S. Overexpression of D-amino acid oxidase prevents retinal neurovascular pathologies in diabetic rats. Diabetologia. 2021;64:693-706.
Not in our library10.1007/s00125-020-05333-y
216.
Sergeys J, et al. Longitudinal in vivo characterization of the streptozotocin-induced diabetic mouse model: focus on early inner retinal responses. Invest. Ophthalmol. Vis. Sci. 2019;60:807-822.
Not in our library10.1167/iovs.18-25372
217.
Binet F, et al. Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy. Science. 2020;369:eaay5356.
Not in our library10.1126/science.aay5356
218.
Sans M, et al. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology. 1999;116:874-883.
Not in our library10.1016/s0016-5085(99)70070-3
219.
Lessieur EM, et al. ICAM-1 on the luminal surface of endothelial cells is induced to a greater extent in mouse retina than in other tissues in diabetes. Diabetologia. 2022;65:1734-1744.
Not in our library10.1007/s00125-022-05719-0
220.
Portillo J-AC, et al. Disruption of retinal inflammation and the development of diabetic retinopathy in mice by a CD40-derived peptide or mutation of CD40 in Müller cells. Diabetologia. 2022;65:2157-2171.
Not in our library10.1007/s00125-022-05775-6
221.
Giblin MJ, et al. Nuclear factor of activated T-cells (NFAT) regulation of IL-1β-induced retinal vascular inflammation. Biochim. Biophys. Acta Mol. Basis Dis. 2021;1867:166238.
Not in our library10.1016/j.bbadis.2021.166238
222.
Giblin MJ, Ontko CD, Penn JS. Effect of cytokine-induced alterations in extracellular matrix composition on diabetic retinopathy-relevant endothelial cell behaviors. Sci. Rep. 2022;12:12955.
Not in our library10.1038/s41598-022-12683-7
223.
Liu X, et al. IL-1β induces IL-6 production in retinal Müller cells predominantly through the activation of p38 MAPK/NF-κB signaling pathway. Exp. Cell Res. 2015;331:223-231.
Not in our library10.1016/j.yexcr.2014.08.040
224.
Feng S, et al. Levels of inflammatory cytokines IL-1, IL-6, IL-8, IL-17A, and TNF- in aqueous humour of patients with diabetic retinopathy. J. Diabetes Res. 2018;2018:8546423.
Not in our library10.1155/2018/8546423
225.
Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799.
Not in our library10.1016/j.redox.2020.101799
226.
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010;107:1058-1070.
Not in our library10.1161/circresaha.110.223545
227.
Geraldes P, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat. Med. 2009;15:1298-1306.
Not in our library10.1038/nm.2052
228.
Suo L, et al. METTL3-mediated -methyladenosine modification governs pericyte dysfunction during diabetes-induced retinal vascular complication. Theranostics. 2022;12:277-289.
Not in our library10.7150/thno.63441
229.
Chang K-C, Snow A, LaBarbera DV, Petrash JM. Aldose reductase inhibition alleviates hyperglycemic effects on human retinal pigment epithelial cells. Chem. Biol. Interact. 2015;234:254-260.
Not in our library10.1016/j.cbi.2014.10.007
230.
Chen H, et al. MD2 blockade prevents modified LDL-induced retinal injury in diabetes by suppressing NADPH oxidase-4 interaction with Toll-like receptor-4. Exp. Mol. Med. 2021;53:681-694.
Not in our library10.1038/s12276-021-00607-w
231.
Liu XY, et al. Shabyar ameliorates high glucose induced retinal pigment epithelium injury through suppressing aldose reductase and AMPK/mTOR/ULK1 autophagy pathway. Front. Pharmacol. 2022;13:852945.
Not in our library10.3389/fphar.2022.852945
232.
Mahmoud AM, Abd El-Twab SM, Abdel-Reheim ES. Consumption of polyphenol-rich Morus alba leaves extract attenuates early diabetic retinopathy: the underlying mechanism. Eur. J. Nutr. 2017;56:1671-1684.
Not in our library10.1007/s00394-016-1214-0
233.
Winges A, et al. Osmotic expression of aldose reductase in retinal pigment epithelial cells: involvement of NFAT5. Graefe’s Arch. Clin. Exp. Ophthalmol. 2016;254:2387-2400.
Not in our library10.1007/s00417-016-3492-x
234.
Xue J, et al. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry. 2014;53:3327-3335.
Not in our library10.1021/bi500046t
235.
Sun L, et al. Advanced glycation end products promote VEGF expression and thus choroidal neovascularization via Cyr61-PI3K/AKT signaling pathway. Sci. Rep. 2017;7:14925.
Not in our library10.1038/s41598-017-14015-6
236.
Kang M-K, et al. Chrysin ameliorates malfunction of retinoid visual cycle through blocking activation of AGE-RAGE-ER stress in glucose-stimulated retinal pigment epithelial cells and diabetic eyes. Nutrients. 2018;10:1046.
Not in our library10.3390/nu10081046
237.
Cui J, Gong R, Hu S, Cai L, Chen L. Gambogic acid ameliorates diabetes-induced proliferative retinopathy through inhibition of the HIF-1α/VEGF expression via targeting PI3K/AKT pathway. Life Sci. 2018;192:293-303.
Not in our library10.1016/j.lfs.2017.11.007
238.
Xie W, et al. Corrigendum: ginsenoside Re attenuates high glucose-induced RF/6A injury regulating PI3K/AKT inhibited HIF-1a/VEGF signaling pathway. Front. Pharmacol. 2020;11:1312.
Not in our library10.3389/fphar.2020.01312
239.
Wang Y, et al. Calcium dobesilate restores autophagy by inhibiting the VEGF/PI3K/AKT/mTOR signaling pathway. Front. Pharmacol. 2019;10:886.
Not in our library10.3389/fphar.2019.00886
240.
Fahmideh F, et al. Effect of troxerutin in counteracting hyperglycemia-induced VEGF upregulation in endothelial cells: a new option to target early stages of diabetic retinopathy? Front. Pharmacol. 2022;13:951833.
Not in our library10.3389/fphar.2022.951833
241.
Zhang H, et al. The effect of total lignans from Fructus Arctii on streptozotocin-induced diabetic retinopathy in Wistar rats. J. Ethnopharmacol. 2020;255:112773.
Not in our library10.1016/j.jep.2020.112773
242.
Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy · 2021
Not checked
243.
Abu El-Asrar AM, et al. The proinflammatory and proangiogenic macrophage migration inhibitory factor is a potential regulator in proliferative diabetic retinopathy. Front. Immunol. 2019;10:2752.
Not in our library10.3389/fimmu.2019.02752
244.
Li Y, et al. Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB-VCAM-1 axis. Sci. Adv. 2020;6:eaaz7815.
Not in our library10.1126/sciadv.aaz7815
245.
Thounaojam MC, et al. Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy. Proc. Natl Acad. Sci. USA. 2017;114:13248-13253.
Not in our library10.1073/pnas.1718592114
246.
Jung S-H, Kim YS, Lee Y-R, Kim JS. High glucose-induced changes in hyaloid-retinal vessels during early ocular development of zebrafish: a short-term animal model of diabetic retinopathy. Br. J. Pharmacol. 2016;173:15-26.
Not in our library10.1111/bph.13279
247.
Liu K, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br. J. Ophthalmol. 2022;106:1436-1443.
Not in our library10.1136/bjophthalmol-2020-318690
248.
Uludag G, et al. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further? Expert Opin. Biol. Ther. 2022;22:1275-1291.
Not in our library10.1080/14712598.2022.2100694
249.
Jhaveri CD, et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. N. Engl. J. Med. 2022;387:692-703.
Not in our library10.1056/nejmoa2204225
250.
Gu X, et al. Glucocorticoids promote extracellular matrix component remodeling by activating YAP in human retinal capillary endothelial cells. Front. Cell Dev. Biol. 2021;9:738341.
Not in our library10.3389/fcell.2021.738341
251.
Shah AD, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015;3:105-113.
Not in our library10.1016/s2213-8587(14)70219-0
252.
Verma S, et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation. 2018;137:405-407.
Not in our library10.1161/circulationaha.117.032031
253.
Anand SS, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J. Am. Coll. Cardiol. 2018;71:2306-2315.
Not in our library10.1016/j.jacc.2018.03.008
254.
Aday AW, Matsushita K. Epidemiology of peripheral artery disease and polyvascular disease. Circ. Res. 2021;128:1818-1832.
Not in our library10.1161/circresaha.121.318535
255.
Lim JZ, Ng NS, Thomas C. Prevention and treatment of diabetic foot ulcers. J. R. Soc. Med. 2017;110:104-109.
Not in our library10.1177/0141076816688346
256.
Mohammedi K, et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol. 2016;15:129.
Not in our library10.1186/s12933-016-0446-x
257.
Ergul A. Endothelin-1 and diabetic complications: focus on the vasculature. Pharm. Res. 2011;63:477-482.
Not in our library10.1016/j.phrs.2011.01.012
258.
Kirthi V, et al. Prevalence of peripheral neuropathy in pre-diabetes: a systematic review. BMJ Open Diabetes Res. Care. 2021;9:e002040.
Not in our library10.1136/bmjdrc-2020-002040
259.
Vas PRJ, Alberti KG, Edmonds ME. Prediabetes: moving away from a glucocentric definition. Lancet Diabetes Endocrinol. 2017;5:848-849.
Not in our library10.1016/s2213-8587(17)30234-6
260.
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses · 2020
No notice
261.
Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr. Diab Rep. 2019;19:86.
Not in our library10.1007/s11892-019-1212-8
262.
Bongaerts BW, et al. Postchallenge hyperglycemia is positively associated with diabetic polyneuropathy: the KORA F4 study. Diabetes Care. 2012;35:1891-1893.
Not in our library10.2337/dc11-2028
263.
Held C, et al. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial. J. Am. Heart Assoc. 2017;6:e005077.
Not in our library10.1161/jaha.116.005077
264.
Wallentin L, et al. Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease. J. Am. Heart Assoc. 2016;5:e003407.
Not in our library10.1161/jaha.116.003407
265.
Garg PK, et al. Lipoprotein-associated phospholipase A2 and incident peripheral arterial disease in older adults: the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol. 2016;36:750-756.
Not in our library10.1161/atvbaha.115.306647
266.
Cheng Z, Zhang C, Mi Y. IL-6 gene rs1800795 polymorphism and diabetes mellitus: a comprehensive analysis involving 42,150 participants from a meta-analysis. Diabetol. Metab. Syndr. 2022;14:95.
Not in our library10.1186/s13098-022-00851-8
267.
Danielsson P, Truedsson L, Eriksson KF, Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc. Med. 2005;10:191-198.
Not in our library10.1191/1358863x05vm617oa
268.
Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am. J. Physiol. Ren. Physiol. 2003;284:F1138-F1144.
Not in our library10.1152/ajprenal.00315.2002
269.
Bönhof GJ, et al. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr. Rev. 2019;40:153-192.
Not in our library10.1210/er.2018-00107
270.
Roustit M, Loader J, Deusenbery C, Baltzis D, Veves A. Endothelial dysfunction as a link between cardiovascular risk factors and peripheral neuropathy in diabetes. J. Clin. Endocrinol. Metab. 2016;101:3401-3408.
Not in our library10.1210/jc.2016-2030
271.
Schamarek I, et al. Adiponectin, markers of subclinical inflammation and nerve conduction in individuals with recently diagnosed type 1 and type 2 diabetes. Eur. J. Endocrinol. 2016;174:433-443.
Not in our library10.1530/eje-15-1010
272.
Chapouly C, et al. Impaired Hedgehog signalling-induced endothelial dysfunction is sufficient to induce neuropathy: implication in diabetes. Cardiovasc. Res. 2016;109:217-227.
Not in our library10.1093/cvr/cvv263
273.
Wang L, et al. Exosomes derived from Schwann cells ameliorate peripheral neuropathy in type 2 diabetic mice. Diabetes. 2020;69:749-759.
Not in our library10.2337/db19-0432
274.
Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93:1296-1313.
Not in our library10.1016/j.neuron.2017.02.005
275.
Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK/eNOS pathway in diabetic mice · 2016
No notice
276.
Akintoye OO, et al. Diabetic neuropathy is associated with increased pain perception, low serum beta-endorphin and increase insulin resistance among Nigerian cohorts in Ekiti State. Heliyon. 2020;6:e04377.
Not in our library10.1016/j.heliyon.2020.e04377
277.
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharm. 2014;18:1-14.
Not in our library10.4196/kjpp.2014.18.1.1
278.
Gene therapy for diabetic peripheral neuropathy: A randomized, placebo‐controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor · 2021
Not checked
279.
Cortese A, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat. Genet. 2020;52:473-481.
Not in our library10.1038/s41588-020-0615-4
280.
Das SK, Yuan YF, Li MQ. Specific PKC βII inhibitor: one stone two birds in the treatment of diabetic foot ulcers. Biosci. Rep. 2018;38:BSR20171459.
Not in our library10.1042/bsr20171459
281.
Elafros MA, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 2022;21:922-936.
Not in our library10.1016/s1474-4422(22)00188-0
282.
Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions. Pharm. Res. 2014;80:21-35.
Not in our library10.1016/j.phrs.2013.12.005
283.
Rumora AE, et al. The divergent roles of dietary saturated and monounsaturated fatty acids on nerve function in murine models of obesity. J. Neurosci. 2019;39:3770-3781.
Not in our library10.1523/jneurosci.3173-18.2019
284.
Zuellig RA, et al. Deoxysphingolipids, novel biomarkers for type 2 diabetes, are cytotoxic for insulin-producing cells. Diabetes. 2014;63:1326-1339.
Not in our library10.2337/db13-1042
285.
Guo SC, et al. Exosomes derived from platelet-rich plasma promote the re-epithelization of chronic cutaneous wounds via activation of YAP in a diabetic rat model. Theranostics. 2017;7:81-96.
Not in our library10.7150/thno.16803
286.
Akbar N, et al. Rapid neutrophil mobilisation by VCAM-1+ endothelial extracellular vesicles. Cardiovasc. Res. 2022;4:cvac012.
Not in our library10.1093/cvr/cvac012
287.
Penno A, et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J. Biol. Chem. 2010;285:11178-11187.
Not in our library10.1074/jbc.m109.092973
288.
Wassmann S, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ. Res. 2004;94:534-541.
Not in our library10.1161/01.res.0000115557.25127.8d
289.
Lachin JM, et al. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes Care. 2017;40:777-783.
Not in our library10.2337/dc16-2426
290.
Qaseem A, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann. Intern. Med. 2018;168:569-576.
Not in our library10.7326/m17-0939
291.
Li H, Horke S, Förstermann U. Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharm. Sci. 2013;34:313-319.
Not in our library10.1016/j.tips.2013.03.007
292.
Paul SK, Bhatt DL, Montvida O. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. Eur. Heart J. 2021;42:1728-1738.
Not in our library10.1093/eurheartj/ehaa956
293.
Verma S, et al. Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial. Circulation. 2018;137:2179-2183.
Not in our library10.1161/circulationaha.118.033898
294.
Sarwar N, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-2222.
Not in our library10.1016/s0140-6736(10)60484-9
295.
Mohan V, Deepa R, Rani SS, Premalatha G. Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India: the Chennai Urban Population Study (CUPS No. 5). J. Am. Coll. Cardiol. 2001;38:682-687.
Not in our library10.1016/s0735-1097(01)01415-2
296.
Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat. Rev. Nephrol. 2020;16:377-390.
Not in our library10.1038/s41581-020-0278-5
297.
Dabelea D, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA. 2017;317:825-835.
Not in our library10.1001/jama.2017.0686
298.
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial · 2021
No notice
299.
Oyama K, et al. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur. Heart J. 2022;43:2958-2967.
Not in our library10.1093/eurheartj/ehab530
300.
Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009;360:129-139.
Not in our library10.1056/nejmoa0808431
301.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359:1577-1589.
Not in our library10.1056/nejmoa0806470
302.
Holman N, Young B, Gadsby R. Current prevalence of type 1 and type 2 diabetes in adults and children in the UK. Diabet. Med. 2015;32:1119-1120.
Not in our library10.1111/dme.12791
303.
Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977-986.
Not in our library10.1056/nejm199309303291401
304.
Chi ZS, Lee ET, Lu M, Keen H, Bennett PH. Vascular disease prevalence in diabetic patients in China: standardised comparison with the 14 centres in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44:S82-S86.
Not in our library10.1007/pl00002944
305.
Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis · 2010
No notice
306.
Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220-2224.
Not in our library10.2337/dc11-1108
307.
Eppens MC, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29:1300-1306.
Not in our library10.2337/dc05-2470
308.
Of mice and men: models and mechanisms of diabetic cardiomyopathy · 2018
No notice
309.
Experimental Diabetes Mellitus in Different Animal Models · 2016
No notice
310.
Poittevin M, et al. Diabetic microangiopathy: impact of impaired cerebral vasoreactivity and delayed angiogenesis after permanent middle cerebral artery occlusion on stroke damage and cerebral repair in mice. Diabetes. 2015;64:999-1010.
Not in our library10.2337/db14-0759
311.
Fan B, et al. Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes. Diabetologia. 2020;63:431-443.
Not in our library10.1007/s00125-019-05043-0
312.
Daniels A, et al. Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling. Acta Physiol. 2010;200:11-22.
Not in our library10.1111/j.1748-1716.2010.02102.x
313.
Yorek MS, et al. Effect of glycemic control on corneal nerves and peripheral neuropathy in streptozotocin-induced diabetic C57Bl/6J mice. J. Peripher. Nerv. Syst. 2014;19:205-217.
Not in our library10.1111/jns.12086
314.
Elmadbouh I, Singla DK. BMP-7 attenuates inflammation-induced pyroptosis and improves cardiac repair in diabetic cardiomyopathy. Cells. 2021;10:2640.
Not in our library10.3390/cells10102640
315.
An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2006;291:H1489-H1506.
Not in our library10.1152/ajpheart.00278.2006
316.
Boudina S, et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation. 2009;119:1272-1283.
Not in our library10.1161/circulationaha.108.792101
317.
Kim SM, et al. Targeting T helper 17 by mycophenolate mofetil attenuates diabetic nephropathy progression. Transl. Res. 2015;166:375-383.
Not in our library10.1016/j.trsl.2015.04.013
318.
Patschan D, et al. eEOC-mediated modulation of endothelial autophagy, senescence, and EnMT in murine diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 2014;307:F686-F694.
Not in our library10.1152/ajprenal.00650.2013
319.
Komeno M, et al. Cardio- and reno-protective effects of dipeptidyl peptidase III in diabetic mice. J. Biol. Chem. 2021;296:100761.
Not in our library10.1016/j.jbc.2021.100761
320.
Sharma G, Ashhar MU, Aeri V, Katare DP. Development and characterization of late-stage diabetes mellitus and -associated vascular complications. Life Sci. 2019;216:295-304.
Not in our library10.1016/j.lfs.2018.11.005
321.
Jeong HY, et al. Chloroquine and amodiaquine enhance AMPK phosphorylation and improve mitochondrial fragmentation in diabetic tubulopathy. Sci. Rep. 2018;8:8774.
Not in our library10.1038/s41598-018-26858-8
322.
Platania CBM, et al. Retinal and circulating miRNA expression patterns in diabetic retinopathy: an in silico and in vivo approach. Br. J. Pharm. 2019;176:2179-2194.
Not in our library10.1111/bph.14665
323.
Bucciarelli LG, et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes. 2008;57:1941-1951.
Not in our library10.2337/db07-0326
324.
Zhao F, Gao X, Ge X, Cui J, Liu X. Cyanidin-3-o-glucoside (C3G) inhibits vascular leakage regulated by microglial activation in early diabetic retinopathy and neovascularization in advanced diabetic retinopathy. Bioengineered. 2021;12:9266-9278.
Not in our library10.1080/21655979.2021.1996512
325.
Rossi S, et al. Activation of melanocortin receptors MC 1 and MC 5 attenuates retinal damage in experimental diabetic retinopathy. Mediators Inflamm. 2016;2016:7368389.
Not in our library10.1155/2016/7368389
326.
Azushima K, Gurley SB, Coffman TM. Modelling diabetic nephropathy in mice. Nat. Rev. Nephrol. 2018;14:48-56.
Not in our library10.1038/nrneph.2017.142
327.
Moriya J, et al. Platelet-derived growth factor C promotes revascularization in ischemic limbs of diabetic mice. J. Vasc. Surg. 2014;59:1402-1409.e1401-1404.
Not in our library10.1016/j.jvs.2013.04.053
328.
Barrot J, et al. Diabetic retinopathy as a predictor of cardiovascular morbidity and mortality in subjects with type 2 diabetes. Front. Med. 2022;9:945245.
Not in our library10.3389/fmed.2022.945245
329.
Cabrera DeBuc D, Somfai GM, Koller A. Retinal microvascular network alterations: potential biomarkers of cerebrovascular and neural diseases. Am. J. Physiol. Heart Circ. Physiol. 2017;312:H201-h212.
Not in our library10.1152/ajpheart.00201.2016
330.
Mordi IR, et al. Prediction of major adverse cardiovascular events from retinal, clinical, and genomic data in individuals with type 2 diabetes: a population cohort study. Diabetes Care. 2022;45:710-716.
Not in our library10.2337/dc21-1124
331.
Ørskov M, Vorum H, Larsen TB, Larsen M, Skjøth F. Retinal artery occlusion as an early indicator of macrovascular complications in diabetes. Am. J. Med. 2022;136:179-185.
Not in our library10.1016/j.amjmed.2022.09.012
332.
Petitti DB, Bhatt H. Retinopathy as a risk factor for nonembolic stroke in diabetic subjects. Stroke. 1995;26:593-596.
Not in our library10.1161/01.str.26.4.593
333.
Cheung N, et al. Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke. 2007;38:398-401.
Not in our library10.1161/01.str.0000254547.91276.50
334.
Hägg S, et al. Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care. 2013;36:4140-4146.
Not in our library10.2337/dc13-0669
335.
Hägg S, et al. Different risk factor profiles for ischemic and hemorrhagic stroke in type 1 diabetes mellitus. Stroke. 2014;45:2558-2562.
Not in our library10.1161/strokeaha.114.005724
336.
Lip GYH, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the loire valley atrial fibrillation project. Chest. 2015;147:1103-1110.
Not in our library10.1378/chest.14-2096
337.
Ong YT, et al. Microvascular structure and network in the retina of patients with ischemic stroke. Stroke. 2013;44:2121-2127.
Not in our library10.1161/strokeaha.113.001741
338.
Mills SA, et al. Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic retinopathy. Proc. Natl Acad. Sci. USA. 2021;118:e2112561118.
Not in our library10.1073/pnas.2112561118
339.
Cheung CY, Ikram MK, Chen C, Wong TY. Imaging retina to study dementia and stroke. Prog. Retin Eye Res. 2017;57:89-107.
Not in our library10.1016/j.preteyeres.2017.01.001
340.
Hughes AD, et al. Association of retinopathy and retinal microvascular abnormalities with stroke and cerebrovascular disease. Stroke. 2016;47:2862-2864.
Not in our library10.1161/strokeaha.116.014998
341.
Vuong LN, et al. Ocular fundus photography of patients with focal neurologic deficits in an emergency department. Neurology. 2015;85:256-262.
Not in our library10.1212/wnl.0000000000001759
342.
Little K, et al. Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. Trends Endocrinol. Metab. 2022;33:50-71.
Not in our library10.1016/j.tem.2021.10.008
343.
Bertoni AG, et al. Diabetic cardiomyopathy and subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2006;29:588-594.
Not in our library10.2337/diacare.29.03.06.dc05-1501
344.
Lee WJ, et al. Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression. Eye. 2014;28:1119-1125.
Not in our library10.1038/eye.2014.130
345.
Kramer CK, Retnakaran R. Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabet. Med. 2013;30:1333-1341.
Not in our library10.1111/dme.12296
346.
Moriya T, et al. Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan Diabetes Complications Study. Diabetes Care. 2013;36:2803-2809.
Not in our library10.2337/dc12-2327
347.
Yamanouchi M, et al. Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease. BMJ Open Diabetes Res. Care. 2019;7:e000726.
Not in our library10.1136/bmjdrc-2019-000726
348.
Park HC, et al. Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. PLoS ONE. 2019;14:e0220506.
Not in our library10.1371/journal.pone.0220506
349.
Broe R, et al. Retinal vessel calibers predict long-term microvascular complications in type 1 diabetes: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987). Diabetes. 2014;63:3906-3914.
Not in our library10.2337/db14-0227
350.
Lee WJ, et al. The relationship between diabetic retinopathy and diabetic nephropathy in a population-based study in Korea (KNHANES V-2, 3). Invest. Ophthalmol. Vis. Sci. 2014;55:6547-6553.
Not in our library10.1167/iovs.14-15001
351.
Bjerg L, et al. Development of microvascular complications and effect of concurrent risk factors in type 1 diabetes: a multistate model from an observational clinical cohort study. Diabetes Care. 2018;41:2297-2305.
Not in our library10.2337/dc18-0679
352.
Lin HT, et al. Diabetic retinopathy as a risk factor for chronic kidney disease progression: a multicenter case(-)control study in Taiwan. Nutrients. 2019;11:509.
Not in our library10.3390/nu11030509
353.
Nusinovici S, et al. Retinal microvascular signs and risk of diabetic kidney disease in asian and white populations. Sci. Rep. 2021;11:4898.
Not in our library10.1038/s41598-021-84464-7
354.
Seo DH, et al. Presence of carotid plaque is associated with rapid renal function decline in patients with type 2 diabetes mellitus and normal renal function. Diabetes Metab. J. 2019;43:840-853.
Not in our library10.4093/dmj.2018.0186
355.
Cardoso CRL, Leite NC, Salles GC, Ferreira MT, Salles GF. Aortic stiffness and ambulatory blood pressure as predictors of diabetic kidney disease: a competing risks analysis from the Rio de Janeiro type 2 diabetes cohort study. Diabetologia. 2018;61:455-465.
Not in our library10.1007/s00125-017-4484-z
356.
Bjornstad P, et al. Predictors of early renal function decline in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes and the Pittsburgh epidemiology of diabetes complications studies. Diabet. Med. 2017;34:1532-1540.
Not in our library10.1111/dme.13430
357.
Teliti M, et al. Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients. Diab. Vasc. Dis. Res. 2018;15:424-432.
Not in our library10.1177/1479164118780808
358.
Orlov S, et al. Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes. Clin. J. Am. Soc. Nephrol. 2015;10:1136-1144.
Not in our library10.2215/cjn.11441114
359.
Monocyte and macrophage immunometabolism in atherosclerosis · 2017
No notice
360.
Chen MY, et al. Profile of crosstalk between glucose and lipid metabolic disturbance and diabetic cardiomyopathy: Inflammation and oxidative stress. Front. Endocrinol. 2022;13:983713.
Not in our library10.3389/fendo.2022.983713
361.
Abe Y, et al. Bioenergetic characterization of mouse podocytes. Am. J. Physiol. Cell Physiol. 2010;299:C464-C476.
Not in our library10.1152/ajpcell.00563.2009
362.
Akude E, et al. Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats. Diabetes. 2011;60:288-297.
Not in our library10.2337/db10-0818
363.
Nakayama Y, Mukai N, Kreitzer G, Patwari P, Yoshioka J. Interaction of ARRDC4 With GLUT1 mediates metabolic stress in the ischemic heart. Circ. Res. 2022;131:510-527.
Not in our library10.1161/circresaha.122.321351
364.
McCrimmon A, et al. Redox phospholipidomics analysis reveals specific oxidized phospholipids and regions in the diabetic mouse kidney. Redox Biol. 2022;58:102520.
Not in our library10.1016/j.redox.2022.102520
365.
Jha AK, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42:419-430.
Not in our library10.1016/j.immuni.2015.02.005
366.
Shirai T, et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J. Exp. Med. 2016;213:337-354.
Not in our library10.1084/jem.20150900
367.
Rohlenova K, Veys K, Miranda-Santos I, De Bock K, Carmeliet P. Endothelial cell metabolism in health and disease. Trends Cell Biol. 2018;28:224-236.
Not in our library10.1016/j.tcb.2017.10.010
368.
Pingle SC, et al. Osmotic diuretics induce adenosine A1 receptor expression and protect renal proximal tubular epithelial cells against cisplatin-mediated apoptosis. J. Biol. Chem. 2004;279:43157-43167.
Not in our library10.1074/jbc.m405666200
369.
Groschner LN, Waldeck-Weiermair M, Malli R, Graier WF. Endothelial mitochondria-less respiration, more integration. Pflug. Arch. 2012;464:63-76.
Not in our library10.1007/s00424-012-1085-z
370.
De Bock K, et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013;154:651-663.
Not in our library10.1016/j.cell.2013.06.037
371.
Iacobini C, Vitale M, Pesce C, Pugliese G, Menini S. Diabetic complications and oxidative stress: a 20-year voyage back in time and back to the future. Antioxidants. 2021;10:727.
Not in our library10.3390/antiox10050727
372.
Klein KR, et al. The SimpliciT1 Study: a randomized, double-blind, placebo-controlled phase 1b/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes. Diabetes Care. 2021;44:960-968.
Not in our library10.2337/dc20-2684
373.
Vella A, et al. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci. Transl. Med. 2019;11:eaau3441.
Not in our library10.1126/scitranslmed.aau3441
374.
Yang W, et al. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 2022;28:974-981.
Not in our library10.1038/s41591-022-01803-5
375.
Zhu D, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018;6:627-636.
Not in our library10.1016/s2213-8587(18)30105-0
376.
Zhu D, et al. Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 2022;28:965-973.
Not in our library10.1038/s41591-022-01802-6
377.
Zhu XX, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diabetes Obes. Metab. 2018;20:2113-2120.
Not in our library10.1111/dom.13338
378.
Lei L, et al. Antidiabetic potential of a novel dual-target activator of glucokinase and peroxisome proliferator activated receptor-γ. Metabolism. 2015;64:1250-1261.
Not in our library10.1016/j.metabol.2015.06.014
379.
Xu X, et al. Glucokinase in stellate ganglia cooperates with P2X3 receptor to develop cardiac sympathetic neuropathy in type 2 diabetes rats. Brain Res. Bull. 2020;165:290-297.
Not in our library10.1016/j.brainresbull.2020.10.004
380.
Du X, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 2003;112:1049-1057.
Not in our library10.1172/jci18127
381.
Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal. 2014;20:1126-1167.
Not in our library10.1089/ars.2012.5149
382.
Chatham JC, Young ME, Zhang J. Role of O-linked N-acetylglucosamine (O-GlcNAc) modification of proteins in diabetic cardiovascular complications. Curr. Opin. Pharm. 2021;57:1-12.
Not in our library10.1016/j.coph.2020.08.005
383.
Caon I, et al. Cell energy metabolism and hyaluronan synthesis. J. Histochem. Cytochem. 2021;69:35-47.
Not in our library10.1369/0022155420929772
384.
Eelen G, de Zeeuw P, Simons M, Carmeliet P. Endothelial cell metabolism in normal and diseased vasculature. Circ. Res. 2015;116:1231-1244.
Not in our library10.1161/circresaha.116.302855
385.
Zhao RZ, Jiang S, Zhang L, Yu ZB. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J. Mol. Med. 2019;44:3-15.
Not in our library10.3892/ijmm.2019.4188
386.
Hwang YC, et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J. 2004;18:1192-1199.
Not in our library10.1096/fj.03-1400com
387.
Vikramadithyan RK, et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest. 2005;115:2434-2443.
Not in our library10.1172/jci24819
388.
Mauer SM, Steffes MW, Azar S, Brown DM. Effects of sorbinil on glomerular structure and function in long-term-diabetic rats. Diabetes. 1989;38:839-846.
Not in our library10.2337/diab.38.7.839
389.
Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS. Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev. Med. Chem. 2016;16:120-162.
Not in our library10.2174/1389557515666150909143737
390.
White PJ, et al. The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase. Cell Metab. 2018;27:1281-1293.e1287.
Not in our library10.1016/j.cmet.2018.04.015
391.
Yoneshiro T, et al. BCAA catabolism in brown fat controls energy homeostasis through SLC25A44. Nature. 2019;572:614-619.
Not in our library10.1038/s41586-019-1503-x
392.
Coqueiro AY, Rogero MM, Tirapegui J. Glutamine as an anti-fatigue amino acid in sports nutrition. Nutrients. 2019;11:863.
Not in our library10.3390/nu11040863
393.
Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation · 2018
No notice
394.
Dollet L, et al. Glutamine regulates skeletal muscle immunometabolism in type 2 diabetes. Diabetes. 2022;71:624-636.
Not in our library10.2337/db20-0814
395.
Samocha-Bonet D, Chisholm DJ, Holst JJ, Greenfield JR. L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients. Nutrients. 2015;7:2101-2108.
Not in our library10.3390/nu7042101
396.
Wang Y, et al. Berberine slows the progression of prediabetes to diabetes in Zucker diabetic fatty rats by enhancing intestinal secretion of glucagon-like peptide-2 and improving the gut microbiota. Front. Endocrinol. 2021;12:609134.
Not in our library10.3389/fendo.2021.609134
397.
Huang H, et al. Role of glutamine and interlinked asparagine metabolism in vessel formation. EMBO J. 2017;36:2334-2352.
Not in our library10.15252/embj.201695518
398.
Tavakoli S, et al. Characterization of macrophage polarization states using combined measurement of 2-deoxyglucose and glutamine accumulation: implications for imaging of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2017;37:1840-1848.
Not in our library10.1161/atvbaha.117.308848
399.
Qi L, et al. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. JAMA. 2013;310:821-828.
Not in our library10.1001/jama.2013.276305
400.
Napolitano G, et al. A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome. Nature. 2020;585:597-602.
Not in our library10.1038/s41586-020-2444-0
401.
Bodineau C, Tomé M, Murdoch PDS, Durán RV. Glutamine, MTOR and autophagy: a multiconnection relationship. Autophagy. 2022;18:2749-2750.
Not in our library10.1080/15548627.2022.2062875
402.
Mathew AV, et al. Impaired amino acid and TCA metabolism and cardiovascular autonomic neuropathy progression in type 1 diabetes. Diabetes. 2019;68:2035-2044.
Not in our library10.2337/db19-0145
403.
Zügner E, et al. Differential in vitro effects of SGLT2 inhibitors on mitochondrial oxidative phosphorylation, glucose uptake and cell metabolism. Int. J. Mol. Sci. 2022;23:7966.
Not in our library10.3390/ijms23147966
404.
Kucharzewska P, Welch JE, Svensson KJ, Belting M. Ornithine decarboxylase and extracellular polyamines regulate microvascular sprouting and actin cytoskeleton dynamics in endothelial cells. Exp. Cell Res. 2010;316:2683-2691.
Not in our library10.1016/j.yexcr.2010.05.033
405.
Kövamees O, et al. Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2016;101:3952-3958.
Not in our library10.1210/jc.2016-2007
406.
Park SY, et al. Dietary glutamic acid and aspartic acid as biomarkers for predicting diabetic retinopathy. Sci. Rep. 2021;11:7244.
Not in our library10.1038/s41598-021-83165-5
407.
Viribay A, Burgos J, Fernández-Landa J, Seco-Calvo J, Mielgo-Ayuso J. Effects of arginine supplementation on athletic performance based on energy metabolism: a systematic review and meta-analysis. Nutrients. 2020;12:1300.
Not in our library10.3390/nu12051300
408.
Red Blood Cell and Endothelial eNOS Independently Regulate Circulating Nitric Oxide Metabolites and Blood Pressure · 2021
No notice
409.
Zhang G, et al. A ternary synergistic eNOS gene delivery system based on calcium ion and L-arginine for accelerating angiogenesis by maximizing NO production. Int. J. Nanomed. 2022;17:1987-2000.
Not in our library10.2147/ijn.s363168
410.
Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
Not in our library10.1038/333664a0
411.
Kovamees O, Shemyakin A, Eriksson M, Angelin B, Pernow J. Arginase inhibition improves endothelial function in patients with familial hypercholesterolaemia irrespective of their cholesterol levels. J. Intern Med. 2016;279:477-484.
Not in our library10.1111/joim.12461
412.
Amelio I, Cutruzzolá F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem. Sci. 2014;39:191-198.
Not in our library10.1016/j.tibs.2014.02.004
413.
Tibbetts AS, Appling DR. Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annu. Rev. Nutr. 2010;30:57-81.
Not in our library10.1146/annurev.nutr.012809.104810
414.
Yu W, et al. One-carbon metabolism supports S-adenosylmethionine and histone methylation to drive inflammatory macrophages. Mol. Cell. 2019;75:1147-1160.e1145.
Not in our library10.1016/j.molcel.2019.06.039
415.
Liao B, et al. Adipocyte fatty acid-binding protein exacerbates cerebral ischaemia injury by disrupting the blood-brain barrier. Eur. Heart J. 2020;41:3169-3180.
Not in our library10.1093/eurheartj/ehaa207
416.
Bernal-Lopez RM, et al. Modulation of human monocyte CD36 by type 2 diabetes mellitus and other atherosclerotic risk factors. Eur. J. Clin. Invest. 2011;41:854-862.
Not in our library10.1111/j.1365-2362.2011.02475.x
417.
Li X, Kumar A, Carmeliet P. Metabolic pathways fueling the endothelial cell drive. Annu. Rev. Physiol. 2019;81:483-503.
Not in our library10.1146/annurev-physiol-020518-114731
418.
Schoors S, et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature. 2015;520:192-197.
Not in our library10.1038/nature14362
419.
Genois MM, et al. CARM1 regulates replication fork speed and stress response by stimulating PARP1. Mol. Cell. 2021;81:784-800.e788.
Not in our library10.1016/j.molcel.2020.12.010
420.
Sun J, et al. PARP1 is upregulated by hyperglycemia via N6-methyladenosine modification and promotes diabetic retinopathy. Disco. Med. 2022;34:115-129.
Not in our library
421.
Soppert J, Lehrke M, Marx N, Jankowski J, Noels H. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv. Drug Deliv. Rev. 2020;159:4-33.
Not in our library10.1016/j.addr.2020.07.019
422.
Zhao M, et al. Gut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy. Nat. Commun. 2022;13:1757.
Not in our library10.1038/s41467-022-29060-7
423.
Yan J, et al. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation. 2009;119:2818-2828.
Not in our library10.1161/circulationaha.108.832915
424.
Mitochondria, endothelial cell function, and vascular diseases · 2014
No notice
425.
Coughlan MT, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 2009;20:742-752.
Not in our library10.1681/asn.2008050514
426.
Gu MJ, et al. Glycolaldehyde, an advanced glycation end products precursor, induces apoptosis via ROS-mediated mitochondrial dysfunction in renal mesangial cells. Antioxidants. 2022;11:934.
Not in our library10.3390/antiox11050934
427.
Dromparis P, Michelakis ED. Mitochondria in vascular health and disease. Annu. Rev. Physiol. 2013;75:95-126.
Not in our library10.1146/annurev-physiol-030212-183804
428.
Kim YM, et al. ROS-induced ROS release orchestrated by Nox4, Nox2, and mitochondria in VEGF signaling and angiogenesis. Am. J. Physiol. Cell Physiol. 2017;312:C749-c764.
Not in our library10.1152/ajpcell.00346.2016
429.
Xirouchaki CE, et al. Skeletal muscle NOX4 is required for adaptive responses that prevent insulin resistance. Sci. Adv. 2021;7:eabl4988.
Not in our library10.1126/sciadv.abl4988
430.
Chen C, Li L, Zhou HJ, Min W. The role of NOX4 and TRX2 in angiogenesis and their potential cross-talk. Antioxidants. 2017;6:42.
Not in our library10.3390/antiox6020042
431.
Han Y, et al. Reactive oxygen species promote tubular injury in diabetic nephropathy: the role of the mitochondrial ros-txnip-nlrp3 biological axis. Redox Biol. 2018;16:32-46.
Not in our library10.1016/j.redox.2018.02.013
432.
Ciciliot S, Fadini GP. Modulation of obesity and insulin resistance by the redox enzyme and adaptor protein p66(Shc). Int. J. Mol. Sci. 2019;20:985.
Not in our library10.3390/ijms20040985
433.
Bravo-Sagua R, et al. Calcium transport and signaling in mitochondria. Compr. Physiol. 2017;7:623-634.
Not in our library10.1002/cphy.c160013
434.
Liu Z, et al. Diabetes mellitus exacerbates post-myocardial infarction heart failure by reducing sarcolipin promoter methylation. ESC Heart Fail. 2020;7:1935-1948.
Not in our library10.1002/ehf2.12789
435.
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis · 2014
No notice
436.
Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2019;15:569-589.
Not in our library10.1038/s41574-019-0242-2
437.
Bugger H, et al. Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic akita mice. Diabetes. 2009;58:1986-1997.
Not in our library10.2337/db09-0259
438.
Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying molecular mechanisms. J. Cell Physiol. 2019;234:8152-8161.
Not in our library10.1002/jcp.27603
439.
Welsh GI, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab. 2010;12:329-340.
Not in our library10.1016/j.cmet.2010.08.015
440.
Song W, et al. SH2B regulation of growth, metabolism, and longevity in both insects and mammals. Cell Metab. 2010;11:427-437.
Not in our library10.1016/j.cmet.2010.04.002
441.
Osorio H, et al. Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats. J. Nephrol. 2010;23:541-546.
Not in our library
442.
Zhang H, et al. Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice. Am. J. Physiol. Ren. Physiol. 2010;299:F91-F98.
Not in our library10.1152/ajprenal.00021.2010
443.
Chang KC, Liang JT, Tsai PS, Wu MS, Hsu KL. Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br. J. Pharm. 2009;157:1419-1426.
Not in our library10.1111/j.1476-5381.2009.00309.x
444.
Kass DA, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464-1470.
Not in our library10.1161/hc3801.097806
445.
Shapiro BP, et al. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation. 2008;118:1002-1010.
Not in our library10.1161/circulationaha.108.777326
446.
Thijssen DH, Carter SE, Green DJ. Arterial structure and function in vascular ageing: are you as old as your arteries? J. Physiol. 2016;594:2275-2284.
Not in our library10.1113/jp270597
447.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605.
Not in our library10.1161/circulationaha.106.621854
448.
Zhang L, et al. Knockout RAGE alleviates cardiac fibrosis through repressing endothelial-to-mesenchymal transition (EndMT) mediated by autophagy. Cell Death Dis. 2021;12:470.
Not in our library10.1038/s41419-021-03750-4
449.
Ott C, et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411-429.
Not in our library10.1016/j.redox.2013.12.016
450.
Wautier JL, Wautier MP. Cellular and molecular aspects of blood cell-endothelium interactions in vascular disorders. Int. J. Mol. Sci. 2020;21:5315.
Not in our library10.3390/ijms21155315
451.
Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev. Mol. Med. 2009;11:e9.
Not in our library10.1017/s146239940900101x
452.
Li H, et al. Expression and cell distribution of receptor for advanced glycation end-products in the rat cortex following experimental subarachnoid hemorrhage. Brain Res. 2014;1543:315-323.
Not in our library10.1016/j.brainres.2013.11.023
453.
Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res. 2004;95:233-238.
Not in our library10.1161/01.res.0000137876.28454.64
454.
Hu P, Lai D, Lu P, Gao J, He H. ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. Int. J. Mol. Med. 2012;29:613-618.
Not in our library10.3892/ijmm.2012.891
455.
Qin J, et al. AKF-PD alleviates diabetic nephropathy via blocking the RAGE/AGEs/NOX and PKC/NOX Pathways. Sci. Rep. 2019;9:4407.
Not in our library10.1038/s41598-018-36344-w
456.
Hu R, et al. Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-κB/NLRP3 signaling pathway in AGEs-induced HUVECs. Eur. J. Pharm. 2020;867:172797.
Not in our library10.1016/j.ejphar.2019.172797
457.
Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia. 2018;61:29-38.
Not in our library10.1007/s00125-017-4435-8
458.
Zhan J, Chen C, Wang DW, Li H. Hyperglycemic memory in diabetic cardiomyopathy. Front. Med. 2022;16:25-38.
Not in our library10.1007/s11684-021-0881-2
459.
Kowluru RA, Mohammad G. Epigenetic modifications in diabetes. Metabolism. 2022;126:154920.
Not in our library10.1016/j.metabol.2021.154920
460.
Gutierrez JA, et al. Prevalence and outcomes of polyvascular (coronary, peripheral, or cerebrovascular) disease in patients with diabetes mellitus (from the SAVOR-TIMI 53 Trial). Am. J. Cardiol. 2019;123:145-152.
Not in our library10.1016/j.amjcard.2018.09.014
461.
Chinese College of Cardiovascular Physicians, t.P.o.C.E.C.o.t.R.A.a.M.o.P.D.i.P.w.T.D.M.e. Chinese expert consensus on the risk assessment and management of panvascular disease in patients with type 2 diabetes mellitus (2022 edition). 14, 1017-1034 (2022).
Not in our library
462.
Natarajan R. Epigenetic mechanisms in diabetic vascular complications and metabolic memory: the 2020 Edwin Bierman Award Lecture. Diabetes. 2021;70:328-337.
Not in our library10.2337/dbi20-0030
463.
Prattichizzo F, de Candia P, De Nigris V, Nicolucci A, Ceriello A. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: systematic review and meta-analyses of trials according to different scenarios. Metabolism. 2020;110:154308.
Not in our library10.1016/j.metabol.2020.154308
464.
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs · 2020
No notice
465.
Kerru N, Singh-Pillay A, Awolade P, Singh P. Current anti-diabetic agents and their molecular targets: a review. Eur. J. Med. Chem. 2018;152:436-488.
Not in our library10.1016/j.ejmech.2018.04.061
466.
Goswami SK, Ranjan P, Dutta RK, Verma SK. Management of inflammation in cardiovascular diseases. Pharm. Res. 2021;173:105912.
Not in our library10.1016/j.phrs.2021.105912
467.
Jin ZQ. MicroRNA targets and biomarker validation for diabetes-associated cardiac fibrosis. Pharm. Res. 2021;174:105941.
Not in our library10.1016/j.phrs.2021.105941
468.
Lhamyani S, et al. miR-21 mimic blocks obesity in mice: a novel therapeutic option. Mol. Ther. Nucleic Acids. 2021;26:401-416.
Not in our library10.1016/j.omtn.2021.06.019
469.
Liu L, et al. BMP-7 inhibits renal fibrosis in diabetic nephropathy via miR-21 downregulation. Life Sci. 2019;238:116957.
Not in our library10.1016/j.lfs.2019.116957
470.
Lu JM, Zhang ZZ, Ma X, Fang SF, Qin XH. Repression of microRNA-21 inhibits retinal vascular endothelial cell growth and angiogenesis via PTEN dependent-PI3K/Akt/VEGF signaling pathway in diabetic retinopathy. Exp. Eye Res. 2020;190:107886.
Not in our library10.1016/j.exer.2019.107886
471.
Faulkner A, et al. Multi-omics analysis of diabetic heart disease in the db/db model reveals potential targets for treatment by a longevity-associated gene. Cells. 2020;9:1283.
Not in our library10.3390/cells9051283
472.
Lotta LA, et al. A cross-platform approach identifies genetic regulators of human metabolism and health. Nat. Genet. 2021;53:54-64.
Not in our library10.1038/s41588-020-00751-5
473.
Fu Q, et al. Traditional Chinese medicine foot bath combined with acupoint massage for the treatment of diabetic peripheral neuropathy: a systematic review and meta-analysis of 31 RCTs. Diabetes Metab. Res. Rev. 2020;36:e3218.
Not in our library10.1002/dmrr.3218
474.
Wang J, et al. Research progress on traditional Chinese medicine syndromes of diabetes mellitus. Biomed. Pharmacother. 2020;121:109565.
Not in our library10.1016/j.biopha.2019.109565
475.
Rosenstock J, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69-79.
Not in our library10.1001/jama.2018.18269
476.
Gantz I, et al. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc. Diabetol. 2017;16:112.
Not in our library10.1186/s12933-017-0593-8
477.
Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2015;373:232-242.
Not in our library10.1056/nejmoa1501352
478.
Ferrannini G, et al. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur. Heart J. 2021;42:2565-2573.
Not in our library10.1093/eurheartj/ehaa777
479.
Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2019;381:841-851.
Not in our library10.1056/nejmoa1901118
480.
Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2017;377:1228-1239.
Not in our library10.1056/nejmoa1612917
481.
Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2016;375:311-322.
Not in our library10.1056/nejmoa1603827
482.
Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 2015;373:2247-2257.
Not in our library10.1056/nejmoa1509225
483.
Fitchett D, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur. Heart J. 2016;37:1526-1534.
Not in our library10.1093/eurheartj/ehv728
484.
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus · 2018
No notice
485.
Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017;377:644-657.
Not in our library10.1056/nejmoa1611925
486.
Solomon SD, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail. 2022;10:184-197.
Not in our library10.1016/j.jchf.2021.11.006
487.
Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 2019;380:2295-2306.
Not in our library10.1056/nejmoa1811744
488.
Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2019;380:347-357.
Not in our library10.1056/nejmoa1812389
489.
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015;373:2117-2128.
Not in our library10.1056/nejmoa1504720
490.
Bergmark BA, et al. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial. Circulation. 2019;140:1004-1014.
Not in our library10.1161/circulationaha.119.040144
491.
Vaccaro O, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5:887-897.
Not in our library10.1016/s2213-8587(17)30317-0
492.
Erdmann E, Harding S, Lam H, Perez A. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes. Metab. 2016;18:266-273.
Not in our library10.1111/dom.12608
493.
Yoshii H, et al. Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. J. Atheroscler. Thromb. 2014;21:563-573.
Not in our library
494.
Marso SP, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N. Engl. J. Med. 2017;377:723-732.
Not in our library10.1056/nejmoa1615692
495.
Cukierman-Yaffe T, et al. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes Endocrinol. 2014;2:562-572.
Not in our library10.1016/s2213-8587(14)70062-2
496.
Gerstein HC, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 2012;367:319-328.
Not in our library10.1056/nejmoa1203858
497.
The ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care39, 701–708 (2016).
Not in our library10.2337/dc15-2283
498.
Gæde P, et al. Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study. Diabetologia. 2019;62:1575-1580.
Not in our library10.1007/s00125-019-4920-3
499.
Oellgaard J, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia. 2018;61:1724-1733.
Not in our library10.1007/s00125-018-4642-y
500.
Reaven PD, et al. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N. Engl. J. Med. 2019;380:2215-2224.
Not in our library10.1056/nejmoa1806802
501.
Lincoff AM, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014;311:1515-1525.
Not in our library10.1001/jama.2014.3321
502.
Perkovic V, et al. Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial. Diabetes Care. 2020;43:1803-1812.
Not in our library10.2337/dc20-0279
503.
Gerstein HC, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131-138.
Not in our library10.1016/s0140-6736(19)31150-x
504.
Mosenzon O, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515-527.
Not in our library10.1016/s2213-8587(19)30192-5
505.
Ludvik B, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398:583-598.
Not in our library10.1016/s0140-6736(21)01443-4
506.
Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020;383:1436-1446.
Not in our library10.1056/nejmoa2024816
507.
Bhatt DL, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 2021;384:129-139.
Not in our library10.1056/nejmoa2030186
508.
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial · 2021
No notice
509.
Tofte, N. et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diab Endocrinol.8, 301–312 (2020).
Not in our library10.1016/s2213-8587(20)30026-7
510.
Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet393, 1937–1947 (2019).
Not in our library10.1016/s0140-6736(19)30772-x
511.
Fernandes VHR, et al. Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: a randomized controlled trial. Diabetes Metab. 2021;47:101280.
Not in our library10.1016/j.diabet.2021.101280
512.
Wykoff CC, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741-755.
Not in our library10.1016/s0140-6736(22)00018-6
513.
Khanani AM, et al. MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology. 2022;129:974-985.
Not in our library10.1016/j.ophtha.2022.04.028
514.
Kunimoto D, et al. Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology. 2020;127:1331-1344.
Not in our library10.1016/j.ophtha.2020.03.035
515.
Bonora BM, et al. Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial. Diabetologia. 2021;64:2334-2344.
Not in our library10.1007/s00125-021-05532-1
516.
Hancock ML, et al. Insulin receptor associates with promoters genome-wide and regulates gene expression. Cell. 2019;177:722-736.e722.
Not in our library10.1016/j.cell.2019.02.030
517.
Watson LS, et al. Hyperinsulinemia alters insulin receptor presentation and internalization in brain microvascular endothelial cells. Diab. Vasc. Dis. Res. 2022;19:14791641221118626.
Not in our library10.1177/14791641221118626
518.
Mitrofanova A, et al. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease. Nat. Commun. 2019;10:2692.
Not in our library10.1038/s41467-019-10584-4
519.
Riehle C, et al. Insulin receptor substrates differentially exacerbate insulin-mediated left ventricular remodeling. JCI Insight. 2020;5:e134920.
Not in our library10.1172/jci.insight.134920
520.
Rathjen T, et al. Endothelial cell insulin signaling regulates CXCR4 (C-X-C motif chemokine receptor 4) and limits leukocyte adhesion to endothelium. Arterioscler. Thromb. Vasc. Biol. 2022;42:e217-e227.
Not in our library10.1161/atvbaha.122.317476
521.
Sun X, et al. Commutative regulation between endothelial NO synthase and insulin receptor substrate 2 by microRNAs. J. Mol. Cell Biol. 2019;11:509-520.
Not in our library10.1093/jmcb/mjy055
522.
Hashimoto S, et al. Roles of insulin receptor substrates (IRS) in renal function and renal hemodynamics. PLoS ONE. 2020;15:e0242332.
Not in our library10.1371/journal.pone.0242332
523.
Xi G, Shen X, Wai C, White MF, Clemmons DR. Hyperglycemia induces vascular smooth muscle cell dedifferentiation by suppressing insulin receptor substrate-1-mediated p53/KLF4 complex stabilization. J. Biol. Chem. 2019;294:2407-2421.
Not in our library10.1074/jbc.ra118.005398
524.
Yang C, et al. Targeting QKI-7 in vivo restores endothelial cell function in diabetes. Nat. Commun. 2020;11:3812.
Not in our library10.1038/s41467-020-17468-y
525.
Ahmed, T. et al. EPDR1 is a noncanonical effector of insulin-mediated angiogenesis regulated by an endothelial-specific TGF-β receptor complex. J. Biol. Chem.298, 102297 (2022).
Not in our library10.1016/j.jbc.2022.102297
526.
Zong, J. et al. Impact of Insulin Receptor Substrate-1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention. J. Am. Heart Assoc.11, e025058 (2022).
Not in our library10.1161/jaha.121.025058
527.
Oral EA, et al. Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. Cell Metab. 2017;26:157-170.e157.
Not in our library10.1016/j.cmet.2017.06.006
528.
Cheng, Y. C., Chiu, Y. M., Dai, Z. K. & Wu, B. N. Loganin Ameliorates Painful Diabetic Neuropathy by Modulating Oxidative Stress, Inflammation and Insulin Sensitivity in Streptozotocin-Nicotinamide-Induced Diabetic Rats. Cells10, (2021).
Not in our library10.3390/cells10102688
529.
Marfella, R. et al. Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism127, 154936 (2022).
Not in our library10.1016/j.metabol.2021.154936

Cited by papers we hold 4

Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives · 2025
No notice
Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications · 2024
No notice
Neutrophil extracellular traps in homeostasis and disease · 2024
No notice
The cardio-renal-metabolic connection: a review of the evidence · 2023
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.